Podcasts about science aaas

How can science speak to our deepest spiritual yearnings? In this captivating panel discussion held at NeueHouse Manhattan, five prominent scientists and thinkers explore how different ways of knowing—from physics to medicine, from spirituality to ethics—can build meaningful bridges between worlds often seen as separate.The panelists are:Dr. Alan Lightman (physicist and Professor of the Practice of the humanities at MIT, and author of numerous books including most recently, the The Miraculous from the Material) - he was a guest on Season 3Dr. Neil Theise (professor of pathology at the NYU Grossman School of Medicine, pioneer of adult stem stell plasticity and the interstitium, and author of "Notes on Complexity: A Scientific Theory of Connection, Consciousness, and Being,”)Dr. Scarlet Soriano, Executive Director at Duke Health & Well-Being, whose work focuses on the development of equity-based and community-grounded health and well-being interventions;and Dr. Katy Hinman is the Director of Dialogue on Science, Ethics and Religion (DoSER) program at the American Academy for the Advancement of Science (AAAS),The panel was moderated by Dr. Robert Lawrence Kuhn, who is the creator, writer, host and executive producer of Closer To Truth, the long-running public television series and leading global resource on Cosmos, Life, Mind, and Meaning.Together, they discuss: Can spirituality coexist with scientific rationality? How do love, consciousness, and our connection to the universe shape our understanding of life's purpose?This event, sponsored by The John Templeton Foundation and produced by Rohan Routroy and Thirty Eight, explores and debates diverse approaches to consciousness and spirituality in an age of science.Watch the video on YouTube: https://youtu.be/iaUV4QWbZcI#ScienceAndSpirituality #ScienceAndReligion #MeaningOfLife #CloserToTruth #Consciousness #AlanLightman #NeilTheiseSupport the show

Σε αυτό το επεισόδιο ξεκινάμε με Πασχαλινά μυστήρια (γιατί παραλίγο να πέσει 13 Απριλίου!) και καταλήγουμε στις πιο συναρπαστικές εξελίξεις στην κοσμολογία. Μαθαίνουμε γιατί το Voyager συνεχίζει να στέλνει σήμα, πώς το τηλεσκόπιο DESI ίσως αλλάξει το μοντέλο του σύμπαντος, και τι παίζει με τη σκοτεινή ενέργεια που… ίσως και να φρενάρει. Αναφέρουμε επίσης το Vera Rubin, το Nancy Grace Roman και τον νέο «ρεκόρ» νετρίνου από τη Μεσόγειο.Pre-show: Το λάθος του Neil deGrasse Tyson για το ΠάσχαΣχετικό ποστ4x08 - Πότε Πέφτει το Πάσχα;Voyager & πυρηνικά καύσιμα – NASA Turns Off 2 Voyager Science Instruments to Extend MissionDESI και σκοτεινή ενέργεια – The Standard Cosmology Model May Be BreakingΤηλεσκόπιο Vera Rubin – NSF–DOE Vera C. Rubin Observatory Installs LSST Camera on Telescope | NOIRLabJames Webb και περιστρεφόμενοι γαλαξίες – A new puzzling observation by James Webb Space Telescope: Galaxies in the deep universe rotate in the same directionNancy Grace Roman Space Telescope – Το νέο διαστημικό τηλεσκόπιο που έρχεται το 2027 για deep-field χαρτογράφηση γαλαξιών. NASA Successfully Joins Sunshade to Roman Observatory's ‘Exoskeleton'Hubble tension – Το μυστήριο με τις διαφορές στις τιμές της σταθεράς του Hubble ανάλογα με τη μέθοδο μέτρησης. New Distance Measurement Highlights Hubble Tension - Sky & TelescopeΠροσσελήνωση Blue Ghost – Ιδιωτική αποστολή της NASA πετυχαίνει τελικά ασφαλή προσσελήνωση. After Lunar Disappointments, NASA Hits the Jackpot With Blue Ghost Moon Lander - The New York TimesMysterious radio pulses traced to dance of stellar dwarfs | Science | AAASΝετρίνα και ρεκόρ ενέργειας – Ανιχνεύθηκε το πιο ενεργητικό νετρίνο στην ιστορία, από τηλεσκόπιο στη Μεσόγειο. An Ultrahigh Neutrino Detection Makes WavesPost-show: Θέμος ΠΕΝΤΑΚΑΛΟΣ!Επικοινωνίαemail: hello@notatop10.fmInstagram: @notatop10Threads: @notatop10Bluesky: @notatop10.fmWeb: notatop10.fm (00:00:00) Pre-show: Το λάθος του Tyson(00:05:20) Intro(00:05:38) Voyager(00:10:38) DESI και σκοτεινή ενέργεια(00:26:21) Τηλεσκόπιο Vera Rubin(00:29:27) James Webb και περιστρεφόμενοι γαλαξίες(00:33:27) Nancy Grace Roman Space Telescope(00:35:38) Hubble tension(00:40:02) Προσελήνωση Blue Ghost(00:41:25) Slow pulsars(00:43:22) Νετρίνα και ρεκόρ ενέργειας(00:45:35) Outro(00:45:45) Θέμος ΠΕΝΤΑΚΑΛΟΣ

Send us a textOn this episode we speak with Dr. Zafra Lerman about how a love for science is fostering world peace.Zafra Lerman is an American chemist, educator, and humanitarian. She is the President of the Malta Conferences Foundation, which aims to promote peace by bringing together scientists from otherwise hostile countries to discuss science and foster international scientific and technical collaboration. From 1986 to 2010, she chaired the American Chemical Society's Subcommittee on Scientific Freedom and Human Rights. She has been successful in preventing executions, releasing prisoners of conscience from jail and bringing dissidents to freedom. She is the recipient of many awards for education and science diplomacy, including the 1999 Presidential Award from U.S. President Clinton, the 2005 Nyholm Prize for Education from the Royal Society of Chemistry (England), the 2015 Science Diplomacy Award from the American Association for the Advancement of Science (AAAS), the 2016 Andrei Sakharov Award for human rights from the American Physical Society (APS), the 2016 United Nations NOVUS Award for the 16th Sustainable Development Goal: Peace and Justice, and the 2017 International Union of Pure and Applied Chemistry Distinguished Women in Chemistry or Chemical Engineering Award.https:/natureandsciencepodcast.com

Sanyin Siang shares highlights from her journey, and how to accept positive affirmations and constructive criticism as data points in your life, importance of being generous, and how to be vulnerable.Sanyin helps leaders launch and create value by focusing on mindset, behavioral change, and team and culture building. Sanyin is a CEO Coach, Advisor, Author,the Executive Director of Duke University's Fuqua/Coach K Center on Leadership & Ethics (COLE) and a Professor with its Pratt School of Engineering.The COLE center is a leadership laboratory that engages all of Duke's Daytime MBA students and convenes high-level think tank gatherings to explore today's complex leadership opportunities and challenges.Sanyin coaches C-suite executives and is in the original cohort of Marshall Goldsmith's 100 Coaches. She is an advisor for GV (former Google Ventures), Duke Corporate Education, and the Sports Innovation Lab. Her thought leadership has appeared in Forbes, Fortune, The Wall Street Journal, and CNN. She has more than 1 million LinkedIn followers. She is a LinkedIn 2017 & 2018 Top 10 Influencer and a 2018 Thinkers50 On the Radar.Sanyin's board service has included those of The Emily K Center, The Museum of Life & Science, Duke Children's Hospital & Health Center. She is a Sr. Advisor with Dan Ariely's Center for Advanced Hindsight and a faculty with StoryLab at Duke. She has spoken to audiences from the White House to Global Sports Management and Owners Summits.Prior to Duke, Sanyin worked at the American Association for the Advancement of Science (AAAS), the world's largest federation of scientific and engineering societies, and publisher of Science. Her initiatives explored the ethical, social, and legal implications of technological advances before they became reality.Her book The Launch Book: Motivational Stories for Launching Your Idea, Business, or Next Career, uses behavioral science principles to help readers build the mindset for addressing major change.Sanyin received a BSE in Biomedical Engineering and an MBA from Duke University.Order "The Launch Book": https://www.amazon.com/gp/product/B074JC5L9V/ref=dbs_a_def_rwt_bibl_vppi_i0

With support from the Institute of Museum and Library Services, AMSEcast is celebrating 250 years of American innovation with expert interviews. CEO of the American Association for the Advancement of Science and executive publisher of Science, Dr. Sudip Parikh joins Alan on this episode to explore the forces shaping scientific progress. He highlights interdisciplinary collaboration, the impact of immigration on innovation, and the need for clear communication in securing research funding. Dr. Parikh also discusses the evolution of U.S. science policy, the role of private investment, and the importance of modernizing dissemination methods. He stresses inspiring future scientists and reducing financial barriers in STEM to sustain American leadership in research and discovery.     Guest Bio Dr. Sudip Parikh is the 19th CEO of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals, a role he assumed in January 2020. With a background in journalism and materials science from the University of North Carolina and a PhD in macromolecular structure and chemistry from the Scripps Research Institute, Dr. Parikh has built a distinguished career at the intersection of science and policy. He has served as a science advisor to the Senate Appropriations Committee, vice president at Battelle, and senior VP at DIA Global, shaping science policy and innovation.     Show Highlights (2:01) What Dr. Parikh thinks are the primary instigators of innovation and the primary obstacles (6:20) The role of immigration in bringing new ideas to the United States (8:20) Sudip's experience gathering support for scientific innovation when working in Washington, D.C. (12:55) Specific policies from Washington that helped spur innovation (16:06) How to strike a balance between disruptive innovations while maintaining our infrastructure and systems (17:43) Dr. Parikh's role as the publisher of the Science family of journals in bringing new ideas to the table versus making small changes (20:18) What processes will have to change for Science and other journals moving forward (22:15) The best ways to inspire that next generation of scientists, engineers, and innovators

Last week, some 3,500 people from across scientific fields gathered in Boston for the annual meeting of the American Association for the Advancement of Science (AAAS). The organization's CEO, Dr. Sudip Parikh, gave a rousing speech to attendees.“Destruction for the ill-conceived notion of cutting costs didn't put an American on the moon, and it didn't wipe smallpox from the face of the Earth,” Parikh said in opening remarks.He was referring, of course, to the huge funding cuts and mass firings happening across federal science and health agencies under the Trump administration. Over the last few weeks, news of these cuts has been frequent—along with the cancellation of grants that include certain prohibited words and the disappearance of data from agency websites.So what's happening, and how should the scientific community respond? Host Flora Lichtman sat down with Dr. Sudip Parikh to discuss the importance of this point in time for American science and technology, what cuts for “efficiency” are getting wrong, and what's at stake in the next few weeks.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Pre-show: Κοπή πίτας, φαγητά στην ξενιτιά Ιστορίες της χρονιάς (2024) Physics - JWST Sees More Galaxies than Expected Physics - Nuclear-Fusion Reaction Beats Breakeven Physics - First Glimpses of the Neutrino Fog First sighting of ‘neutrino fog' sparks excitement – but is it bad news for dark matter? Ανακάλυψη νετρίνων από πειράματα στην Ιταλία και την Κίνα Προοπτικές για τη σκοτεινή ύλη και τα φυσικά μοντέλα Cosmological Evidence Emerges That Dark Energy Is An Illusion | Discover Magazine Νέα μοντέλα κοσμολογίας που αμφισβητούν την ύπαρξη σκοτεινής ύλης Θεωρία Timescape και του τρόπου που ο χρόνος επηρεάζεται από βαρυτικά πεδία Surprisingly thick ice on Jupiter's moon Europa complicates hunt for life | Science | AAAS Ανακαλύψεις για το παχύ κέλυφος πάγου στην Ευρώπη του Δία Επιπτώσεις στις πιθανότητες ύπαρξης ζωής Europe's Maiaspace steps up effort to counter SpaceX with reusable rocket | Reuters Αρνητικά νέα για την Ευρώπη και τους καθυστερημένους επαναχρησιμοποιούμενους πυραύλους Συγκρίσεις με την SpaceX και άλλες πρωτοβουλίες στην Ευρώπη Google passes milestone on road to an error-free quantum computer | Science Researchers Demonstrate Quantum Teleportation over Fiberoptic Cables Carrying Internet Traffic | Sci.News NSF panel says proposed giant telescopes would swamp agency's budget | Science | AAAS NASA Artemis Moon Missions Delayed Until 2026 and 2027 - The New York Times First Rocks Returned from Moon's Far Side Reveal Ancient Volcanic Activity | Scientific American Footprints Suggest Different Human Relatives Lived Alongside One Another - The New York Times When It Comes to Thinking, Our Brains Are Surprisingly Slow | Discover Magazine Νέα δεδομένα για το ανθρώπινο εγκέφαλο και την ταχύτητα μεταφοράς δεδομένων Hera Mission Launches to Witness Asteroid-Crash Aftermath - Sky & Telescope ESA - Eclipse-making double satellite Proba-3 enters orbit Oldest known alphabet unearthed in ancient Syrian city Ανακάλυψη παλαιότερου αλφαβήτου στη Συρία Why eating less slows ageing: this molecule is key NASA's Parker Solar Probe Makes its Record-Breaking Closest Approach to the Sun - Universe Today Το Parker Solar Probe πλησίασε τον ήλιο και επιβίωσε, καταρρίπτοντας ρεκόρ ταχύτητας Post-show Το viral Thread του Θέμου Nosferatu, Squid Game Επικοινωνία email: hello@notatop10.fm Instagram: @notatop10 Threads: @notatop10 Bluesky: @notatop10.fm Web: notatop10.fm     (00:00:00) Pre-show (00:08:13) Intro (00:08:30) Κορυφαίες ειδήσεις του 2024 (00:11:16) Νέφος νετρίνων (00:16:37) Μούφα η σκοτεινή ενέργεια (?) (00:31:56) Η Ευρώπη πάχυνε (00:35:01) υρωπαϊκοί επαναχρησιμοποιούμενοι πυραύλοι (00:44:57) Κβαντικοί υπολογιστές (00:51:45) Οι διάδοχοι του Hubble (00:59:02) Αποστολή Artemis (01:01:29) Οι πέτρες από τη σελήνη (01:02:38) Ανθρώπινα αποτυπώματα (01:07:26) Το throughput του ανθρώπινου μυαλού (01:16:27) Επιστροφή στον αστεροειδή (01:17:43) Εκλείψεις κατά βούληση (01:18:39) Το παλαιότερο αλφάβητο στον κόσμο (01:21:16) Τρώτε λιγότερο για να ζήσετε πολύ (01:25:40) Parker Solar Probe (01:31:01) Post-show

Suitable reading material as edited by Dr Kaeberlein : https://amzn.to/3V9iSzj Today I'm joined by one of the worlds leading experts on ageing Dr Matt Kaeberlein. Dr. Kaeberlein's research is focused on the biological mechanisms of aging in order to help us intervene so that we can maintain good health and quality of life for longer than is currently possible. He has published more than 200 scientific papers, has been recognized by several prestigious awards, and has Fellow status in the American Association for the Advancement of Science (AAAS), the American Aging Association, and the Gerontological Society of America (GSA). Dr. Kaeberlein is currently the CEO of the American Aging Association. Dr. Kaeberlein is the founding Director of the UW Healthy Aging and Longevity Research Institute, the Director of the UW Nathan Shock Center of Excellence in the Basic Biology of Aging, Director of the Biological Mechanisms of Healthy Aging Training Program, and founder and co-Director of the Dog Aging Project. He is also the ceo of Optispan. In this episode we learn about what the difference is betweeen lifespan and health span, we learn about anti-ageing diets. Does calorie restriction for anti - ageing work? We hear about an incredbly interesting drug called rapamycin that increasess the life span of mice by an astonishing 30%. We ask do anti ageing supplements really work and what can we do on a day to day basis to maximise our lifespan Order Happy Habits for Mind and Body Audiobook: https://rb.gy/h5jjjg Order Kindle copy of Happy Habits for Mind and Body : https://rb.gy/jiojcc Order US paperback of Happy Habits for Mind and Body : https://rb.gy/sirste Order UK paperback of Happy Habits for Mind and Body : https://rb.gy/jtfea5 Listen to all previous podcast episodes of the Happy Habit Podcast via these podcast platforms : Apple Podcasts https://podcasts.apple.com/ie/podcast... Amazon https://www.amazon.com/Happy-Habit-Po... Amazon music : https://music.amazon.com/podcasts/670... Spotify https://https://open.spotify.com/show/2VKIhQK... Google Podcasts : https://t.ly/hTU8q ----- Follow the Happy Habit Podcast at: Website: https://happyhabitpodcast.wordpress.c...

The Chief Scientific Advisor at Novo Nordisk, Lotte Bjerre Knudsen, was the key force who pushed hard to develop GLP-1 drugs for treating obesity and subsequently for Alzheimer's. She was recently recognized by the 2024 Lasker Medical Research Award, and the 2024 AAAS Bhaumik Breakthrough of the Year Award. That recognition is richly deserved, since it is unclear if the GLP-1 drug path to obesity treatment, and all of the associated benefits, would have been seen at this time without her influence. That's especially true given the mystery for why people with Type 2 diabetes (for which these drugs were used for many years) did not exhibit much in the way of weight loss. We discussed that and the future of these drugs, including their potential to prevent neurodegenerative diseases. And about dressing up in pink!The Ground Truths podcasts are also available on Apple and Spotify.Our entire conversation can also be seen by video at YouTube along with all of the Ground Truths podcasts. If you like the video format, please subscribe to this channel. Even if you prefer video, please take a look at the transcript with graphics and useful links to citations.A Video Clip below on the barriers of a woman scientist to push Novo Nordisk to develop GLP-1 for obesity. “I was always just been a nerdy little scientist who kind of found home here in this company for 35 years.”—Lotte Bjerre Knudsen, 60 MinutesTranscript with Links to audio and external referencesEric Topol (00:06):Well, hello, it's Eric Topol with Ground Truths, and I have with me a special guest. She's the Chief Science Officer of Novo Nordisk and it's Lotte Bjerre Knudsen, and we're delighted to have her. She's a recent recipient of the Lasker Award, which I think is considered like the pre-Nobel Award here in the United States. And I was involved with her in terms of researching who was the principal person who brought the GLP-1 drugs to the forefront for obesity, and it turned out to be Lotte. So welcome, Lotte.Lotte Bjerre Knudsen (00:48):Thank you very much. And also very, very happy to be here. I'm not the Chief Science Officer for Novo Nordisk, I'm the Chief Scientific Advisor of working for the Chief Science Officer of Novo Nordisk, but maybe too many people, not so different, right?From Laundry Detergents to GLP-1 DrugsEric Topol (01:06):Yes. Thank you, I actually meant to say advisor, but yes, I'm glad you cleared that up. I know from speaking to some of your colleagues, I actually spoke to Robin yesterday that you are looked to very highly, the most highly regarded person in science there, so not surprisingly. What I want to do is first talk about the glucagon-like peptide-1 (GLP-1) that got its legs back in, I guess 1984. So we're going way back. And what's also interesting is that you go way back at Novo Nordisk to 35 years in 1989. And so, there had been this work with this extraordinary hormone and neurotransmitter with a very short half-life that you knew about. But when you first started in Novo Nordisk, you weren't working on this. As I understand it, you're working on laundry detergent enzymes. How did you make this pivot from the laundry enzymes to getting into the GLP-1 world?Lotte Bjerre Knudsen (02:16):Yeah, thank you for that question. I'm from the technical University of Denmark, so I'm trained in biotechnology, and we're a small country, so not that many companies to work for. And I always had my mind set on, I wanted to work for Novo as it was called back then, and it just happened to be in the industrial enzyme part that I got my foot in first. And then I had a very interesting boss at the time. Unfortunately, he's not alive anymore, but he was both a medical doctor as well as a chemist. So he was actually put in charge of actually, let's see if we can do something new in diabetes. And then since he hired me and I had not been there that long, I simply tagged along as the youngest scientist on the team, and then suddenly I became a diabetes researcher. Around the same time, I think you remember that all of pharma was interested in obesity in the early 90s, everyone wanted to do diabetes as well as obesity, but they were separate teams and they all wanted to do small molecules, but it just happens to be so that the best idea we could find at that time was actually GLP-1, because we actually had clinical data relatively early that GLP-1 was a really good candidate as a treatment for diabetes because of the glucose sensitivity of the actions.(03:43):So you'd have efficient lowering of glucose through a dual mechanism with increasing insulin, lowering glucagon, and then it was safe because there wasn't this hypoglycemia you get from insulin. But then I had other colleagues who were working on obesity, and I was just kind of listening, right, what's going on there? And then also a colleague that I had, we had, I don't know if you remember the old Hagedorn Research Institute, but Novo actually had kind of like an academic research institute that was affiliated with us. And there was this group that were working on this glucagon tumor model that produced high levels of glucagon, GLP-1 and PYY. And these rats, they starved themselves to death. And I knew about that from 1994. So that actually inspired my thinking. So when Stephen Bloom's paper came out in January of 1996, and he was the first one to call GLP-1 a neurotransmitter, I think, but I was already way into actually screening these kind of molecules that later then became liraglutide.No One Else Thought About This [Obesity](04:54):And then I thought, why on earth should we not actually do both things at the same time? If we have an idea that can both work in diabetes in a much safer way than in insulin, and then also at the same time work in obesity. But the reality is that no one else thought about this, or if they thought about it, they didn't really think that it would a good idea. But I think I had the luxury of being in a biotech company, so everyone was working with peptides and proteins. So I don't think I got the same challenge that the other people in the other pharma's got when they all wanted small molecules.Eric Topol (05:36):Well, also just to set the foundation here, which you alluded to, there had been so many attempts to come up with a drug that would work, not just of course in diabetes where there are many classes of drugs, but moreover, to treat the condition of obesity. Actually, I was involved with one of them, Rimonabant and did the large trial, which as you know, led to having to stop the drug, discontinue it because it was associated with suicidal ideation and actual some suicide. So there had been such a long history of checkered inability to come up with a drug. But what was striking is the challenge, and this is one of the first important questions about, when you had the extended half-life of the first GLP-1 drug, that instead of having to take multiple times a day, you could actually, with liraglutide get to a point where you were starting to get to an extended half-life. This is now going back to 1997 with approval in 2010, still 14 years ago. But when you came up with this drug, because this was certainly one of your great contributions, this drug was just a step along the way in this kind of iterative process, wouldn't you say? It wasn't the long half-life and the potency that eventually got us to where we are today. Is that true?Lotte Bjerre Knudsen (07:15):Yeah, it was a stepwise process. And what's super interesting about this class of medicines is that they're actually so different. If you talk about a class of medicine where small molecules, they can be different, but they're usually more alike than they're different. And when it comes to this class with these medium-sized peptides, people tried a whole bunch of different things. So they're actually really, really different. Some are simple peptides. So the idea that I came up with was to use this fatty acid isolation principle, and that's then a subclass in the class. And then the first, once weekly, for example, was an antibody-based molecule liraglutide. So they're much, much, much larger molecule compared to the small peptides. So they're very different. And neither the simple peptides nor the really big antibody derived molecules, they don't give a lot of weight loss. So we actually get more weight loss with these kinds of molecules, which is also why you can now see that it has actually kind of inspired a whole industry to kind of try and go and make similar kinds of molecules.Eric Topol (08:27):Well, inspired a whole industry is an understatement. It's become the most extraordinary class of drugs, I think in medical history, having been a student of various, I mean obviously statins have been a major contribution, but this seems to have transcended that already. We're going to talk about more about where things are headed, but this fatty acid acetylation was a major step forward in extending the half-life of the drug, whereby today you can give semaglutide once a week. And this, I think, of course, there are many ways that you might've been able to extend the half-life, but you were starting with a hormone, a natural hormone neurotransmitter that had such an exquisitely short half-life of basically second or minutes rather than that you could give for a week. So I know there were many different ways you could have protected or extended the half-life one way or another, but this seemed to be a breakthrough of many along the chain of breakthroughs. But the question I have is when you were giving this to the diabetics, which was the precedent, that was really what these drugs were first intended, they didn't lose that much weight, and they never, still today when it's looked at for obese non-diabetics versus diabetics, there's a gap in weight loss. Why is that at the exact same dose, with the exact same peptide that the weight loss differs for people with type 2 diabetes as compared to those who have pure obesity?The Mystery of Why People With Type 2 Diabetes Don't Lose Weight Like Those With Obesity Lotte Bjerre Knudsen (10:09):Yeah, I can't give you a molecular answer to that, right. But I think the notion, I think it's the same for example with metformin, even though it gives less weight loss because that has also been tried in both people with diabetes and people without diabetes. So I think it's just for somehow people with diabetes are more resistant to weight loss. I think it's a really good question that I'm hoping maybe we could get through, for example, with proteomics and actually comparing people with diabetes and people without diabetes and looking at people who have the similar kind of weight loss. That could be really interesting. But I really don't have a good molecular answer for you, but it's just a really, really strong fact. But it also leads me to wanting to say it's interesting, because if that had been our motivation to actually say, oh, there's weight loss in diabetes, let's pursue it in people with obesity, I don't think we would've done that because the weight loss in people with diabetes wasn't that impressive. So it was very important for our chain of thought and decision early on that we actually knew that GLP-1 had these separate effects and that they could work in the brain and have a separate effect on well-known pathways in the brain. And that was more our motivation to actually continue to invest in obesity.Eric Topol (11:42):Yeah, no, I think this is when we did the research on the committee for the American Association for Advancement of Science (AAAS) award, the Mani L. Bhaumik Award, that you were recognized for the breakthrough of the year, this year. We tried to scour all the work and we actually had to hit Danish translations and all sorts of other papers they reviewed. And we learned through that process working on this committee that you were the one to be the champion of pushing this towards obesity, and it would've easily been missed because as we've been discussing, the weight loss in people with diabetes was small, but you push for it. And this was an extraordinarily important push because what it has resulted in, of course, has been spectacular. And obviously as we're going to get into much more than just obesity and obesity related conditions. But before we get to those other conditions, and as you've been known in the medical community as “the mother of GLP-1”, you were dubbed that term. The GLP-1 receptor is expressed in many parts of the body. Maybe you could just tell us about the distribution because this, I think is tied into these central nervous system effects that are not just related to the gut hormone type of axis.GLP-1 Receptors and the BrainLotte Bjerre Knudsen (13:17):So I spent a lot of time on that together with my amazing colleague, Charles Pyke, who's an histology expert because it turned out to be so very important. In general, when you're trying to make new medicines, understanding the mechanism, sometimes people say, yeah, who cares? But actually, it should matter, I think because where it becomes really important can be an understanding what they do not do. We've had to do a lot of proving the negatives for GLP-1. We went through these issues with thyroid cancer, pancreatitis, pancreas cancer. In all of that work, it was actually really important that we could show where the GLP-1 receptor was not expressed. So in the pancreas, we know that it's primarily on the insulin producing cells, and then we also have them in the intestine where they're probably involved in regulating inflammation and really creating a much healthier gut.(14:15):And then we have a lot of receptors in the brain. They're typically expressed on neurons, but they're also on astrocytes, they're also on smooth muscle cells. We have them on the heart and the sinus node. That's why there's a small increase in heart rate. We have them in the kidney, on again some smooth muscle cells that are renin positive. So there we can start thinking blood pressure and other things. So it turns out that you can go around the body and there are all of these specific GLP-1 receptor population, that you can see how they tie into the pharmacology. But obviously in physiology, they're not as important as they have turned out to be in pharmacology when we suddenly come with 24 hours a day exposure for a day or a week or for as long as the administration interval is. So, but specifically for obesity, I think it's in the vein, it's hard to, you should always be careful.(15:18):That's something I've learned to never say never. Of course, there could be a contribution from the peripheral nervous system as well to the effects in obesity. But I do think there are so many important and well described neuronal populations that have the GLP-1 receptor and which are accessible from the periphery. So just to mention, maybe one of the most, well-known is a POMC/CART neuron in the hypothalamus. They have the GLP-1 receptor, they're activated, but there also is an inhibitory tone on the AgRP and NPY neurons, and it fits very well with that. We know that people report that they feel more sated, they feel less hungry. But then there are also effects in the hindbrain and in some of the reward centers also have GLP-1 receptors. And we know that also now, we have really good actually clinical studies that show that there is a change in food choice and people can control their food intake better. So I think that fits very well with effects on the reward system. So it's a whole myriad, or maybe you could say that GLP-1 orchestrates a number of different neuronal populations to have these overall effects that reduce energy intake.Eric Topol (16:42):Yeah, it's pretty striking. It's almost like we're all walking around with GLP-1 deficiency, that if we had this present at higher levels around the clock, and of course eventually we'll see things that are well beyond obesity, how well this has an impact. Now, there was an extraordinary review in Cell Metabolism on the brain and GLP-1, and not just the brain, but the essential nervous system, the neurovascular, it's called the “GLP-1 programs and neurovascular landscape.”(17:20):And in this review, it got into the brain effects that were well beyond, I think what are generally appreciated. Not only the protection of the integrity of the blood-brain barrier, this whole neuroglial vascular unit, the myelin sheath protection, reducing inflammation within the brain, improving the glymphatic flow, which is of course critical for clearing waste and promoting cerebral vascular remodeling and more, so the brain effects here is what it seems to be. You mentioned the reward circuit, of course, but the brain effects here seem to be diverse, quite a bit of breath and extraordinary. And as we've seen in the clinic now with the work that's been done, we're seeing things about addiction, even gambling, alcohol, drugs, I mean neuropsychiatric impact, it's pretty profound. Maybe you could comment about that.On to Alzheimer's and Parkinson's DiseasesLotte Bjerre Knudsen (18:23):Yeah. I haven't read that paper yet, but I just saw it earlier. And I have been following this for about actually more than 10 years because when I was kind of over the big work of actually getting the approval for diabetes and obesity. I thought I had a little bit of capacity to actually look at Alzheimer's and Parkinson's disease because I just thought there's such an insane unmet need and what if GLP-1 could actually make a difference? And the first big paper that talked about this was actually in Nature Medicine in 2003, and it was originally, I think I should credit Nigel Greig. Greig, he's from NIH or from NIA, I can't remember, right. But he was actually the first one, I think to say if GLP-1 has all of these important effects in the pancreas and to protect cells, and there are all these GLP-1 receptors in the brain, maybe it also protects neurons.(19:25):So that was the first hypothesis. And the paper on Nature Medicine in 2003 describes how the GLP-1 receptor in the hippocampus is involved in cognition. And then we did a couple of studies in different animal models, and I was, to be honest, really confused. But then there was a new paper in Nature Medicine in 2018 that started to focus in on neuroinflammation. And by that time, I knew much more about inflammation and knew GLP-1 actually lower CRP by about 50% in the different trials. So I was really tuned into the potential importance of that in cardiovascular and kidney disease. But I was like, oh, what if that's also something that is important in the brain? Then it made more sense to me to try and build some evidence for that. So that was how we actually started looking at a hypothesis for Alzheimer's and Parkinson's.(20:21):And we now have a really large phase three study ongoing, but of course, it's a hypothesis, right? And no one has yet, I think, proven that GLP-1 has really important effects on these indications, but we are testing it in 4,000 people with Alzheimer's disease. So our hypothesis is around neuroinflammation, but defined in a way where you could say it's both peripheral inflammation and the effect it has on the vasculature, it's the effect on the blood-brain barrier. It's the astrocytes and the microglia, and there are probably also some T cells that have the GLP-1 receptor that could be important. And then couple that up also with some of the new information from neurons, because there are two papers to think in the last year that has highlighted neurons either in the hindbrain or a little bit further on. Both of them are probably hindbrain populations that actually seem to be really important in regulating both peripheral as well as central information.(21:27):So what if neurons are actually also an overlooked mechanism here, and both of these neuronal populations have the GLP-1 receptor and are accessible from the periphery, even though the child super paper in Nature doesn't mention that, but they do have the GLP-1 receptor. So there are all these different mechanisms that GLP-1 can have an impact on the broad definition maybe of neuroinflammation. And maybe the way one should start thinking about it is to say it's not an anti-inflammatory agent, but maybe it induces homeostasis in these systems. I think that could maybe be a good way to think about it, because I think saying that GLP-1 is anti-inflammatory, I think that that's wrong because that's more for agents that have a really strong effect on one particular inflammatory pathway.Eric Topol (22:22):That's a very important point you're making because I think we conceive of these drugs as anti-inflammatory agents from these more diverse actions that we've just been reviewing. But I like this restoring homeostasis. It's an interesting way to put it. This brings us, you mentioned about the Parkinson's, and when I reviewed the three randomized Parkinson's trials, they're all small, but it appears to be the first disease modifying drug ever in Parkinson's. Of course, these were done with different drugs that were older drugs. We haven't seen the ones that yet to be with semaglutide or other agents. And I wondered if you pushed, just like you did for obesity within Novo Nordisk, you pushed to go into obesity. Did you also force to push for Alzheimer's?Lotte Bjerre Knudsen (23:19):Yes. So that is also me who had to argue for that. I'm happy to do these things. I was born brave. I am happy to do these things.Eric Topol (23:31):That's wonderful. Without you, we would be way behind, and it took decades to get to this point. But look where we are now, especially with all the rigorous trials, the large clinical trials. You're into one right now of some 20,000 participants to see whether not just people with prior heart disease, but people without known heart disease to see whether or not this will have an effect. And there's so much data now, of course, already a completed trial with reduction of heart attacks and strokes. But now to extend this to people who are not such high risk, but these large trials, we keep learning more. Like for example, the reduction of inflammatory markers is occurring even before the weight loss that starts to manifest. So we learned a lot from the trials that are just even beyond some of the major primary outcomes. Would you agree about that?Lotte Bjerre Knudsen (24:34):So I'm not sure we can say that it comes before the weight loss because the energy intake reduction happens instantly. The glycemic response happens instantly. And all of these improvements will of course also have an effect to dampen inflammation. We do not have data that supports that it comes before because we haven't sampled that much in the beginning.Eric Topol (25:04):Okay.Lotte Bjerre Knudsen (25:05):I wouldn't be able to say that, and I don't think there are any, well, it's hard to keep up that the entire literature on GLP-1 these days, but I don't think anyone has actually shown that there is a separation because it's super hard to separate when things are occurring at the same time.Eric Topol (25:24):Yeah, I'm just citing the heart disease trial where in the New England Journal that point was made. But I think your point also that there was already a change in energy intake immediately is apropos for sure. Now, when we get into this new paper of yours, the proteomics, can you tell us about that because that's really exciting. We're in a high throughput proteomics era right now that we can analyze thousands of plasma proteins in any given individual. What are you learning about proteomics with the GLP-1 drug?The GLP-1 Drug Impact on ProteomicsLotte Bjerre Knudsen (26:07):Yeah, yeah. So I'm also the super excited about omics, right? Because I have worked in a wonderful organization of people who can do these large scale clinical trials, and we used to not collect a lot of samples for future use, but we've done that for some years now. So now we have this amazing collection of samples we can learn from and actually both inform the patients and the physicians, but also inform future research. So we have been doing that in our semaglutide trials, and we've just published the proteomics data from the step one and step two trials. So the phase 3a trials that supported the approval of semaglutide for the treatment of obesity. So one of them in people with obesity and one in people with obesity and diabetes, and those data are now published in Nature Medicine. [3 January 2025]. And we were learning a lot of things because you can compare the proteome effects to what has been done in the decode cohort.(27:11):So they have all these disease signature. So that's one thing that you can for sure see, and you can see a lot of things there with hints towards addiction. And then also you can take more predefined signatures also to look into what actually might be driving the cardiovascular risk. So I think there are so many things that you can learn from this, and of course it can also inform when you look at what's actually mediating the effect and probably something around inflammation is important. We have already also shown a more standard mediation analysis that shows that actually the most explainable factor for the effect on MACE [major adverse cardiovascular events] in the select trial is inflammation. It doesn't explain everything, but it actually looks like it's more important than BMI and weight loss. So that's really interesting how much we can learn from there. We're making the data are available at the summary statistic level so people can go and play with them ourselves.(28:23):And I think as we have more different kinds of medicines available in obesity, it's also a way to kind of compare how these different medicines work. And as we get more and more better at maybe also characterizing people with obesity, because I think that's a great thing that's going to happen now is there's going to be more funding for obesity research. Because I think that's what the attention that we are seeing right now is also giving. Then we can better start to understand. We always, we've been saying that people probably have different kinds of obesity, but we don't really know. So now we can actually start to understand that much better and maybe also understand how these different classes of medicines will work if we have the proteome data from different trials.Eric Topol (29:10):No, I'm absolutely fascinated about the proteomics. I call it a quiet revolution because many people don't know about it. [My recent post on this topic here.](29:18):The ability to assess thousands of proteins in each individual, and it's giving us new insights about cause and effect as you alluded to, the relationship with as you said, MACE (major adverse cardiovascular events) and the actions of this drug class. I mean, there's just so much we can learn here from the proteomics. Another thing that's fascinating about the GLP-1 is its effect on epigenetic clocks. And recently at one of the meetings it was presented, this is Steven Horvath that we had on Ground Truths not long ago. He talked about at this talk that for the first time to see that you could basically slow the epigenetic clock with a GLP-1. Is there any further information about that?Lotte Bjerre Knudsen (30:16):Yeah, no. We've never had enough of a sample size to actually be able to look at it, so unfortunately, no. But there is something else, right, because there is this group at the Stanford, Tony Wyss-Coray or something.Eric Topol (30:33):Yes, Tony Wyss-Coray.Lotte Bjerre Knudsen (30:35):Now he published a paper, is it two years ago? Where he did it using proteomics. He defined an anti-aging signature for various different organs.Lotte Bjerre Knudsen (30:46):We are in the process of trying to see if we could take those signatures and apply them on to our data.Eric Topol (30:55):Well, what's interesting is we're pretty close friends, and he, not only that paper you mentioned on organ clocks, which is a phenomenal contribution, but he has a paper coming out soon in Nature Medicine, the preprint is up, and what he showed was that the brain and the immune system was the main organ clocks that were associated with longevity. And so, it takes another step further and it's looking at 11,000 plasma proteins. So it's really interesting how this field is evolving because the omics, as you put it, whether it's proteomics, and now we're learning also about the epigenome and what brings us to the potential that this class of drugs would have an impact on health span in all people, not just those who are obese. Would you project that's going to be possible in the years ahead?Lotte Bjerre Knudsen (32:02):I don't know about health span, but because certainly there's been so many studies with metformin and there's been a lot of wonderful data showing an effect on the epigenetic clocks, but not really an effect on lifespan because that metformin is so widely used. If that was the case, it would be easy to dig those data out of different registries. But certainly a healthier aging is the most obvious one because when you have one class of medicine that actually has so many different effects. Right now we are looking at them at a one by one case, but we really should be looking at them so you are getting the benefits on the heart and the vasculature on the brain and the kidneys and the diabetes and the knees. You're getting all of that at the same time, and that certainly should lead to much, much healthier lives. And then of course, we just need to get people to eat healthier. Also, maybe we should talk a little bit about the food industry. I heard you did that in some of your podcast, right?Eric Topol (33:17):Yes. That is the big food, if you will. It's a big problem, a very big problem, and the ultra-processed foods. And so, lifestyle is not good and trying to compensate for that with a drug intervention strategy is like chasing your tail. So you're absolutely right about that. I mean, I guess what I'm getting into here is that whereas today we keep seeing the effects, whether it's the liver, the kidney, the heart, obesity, and people with diabetes. But for example, in the Alzheimer's trial, do you have to be obese to be enrolled in the Alzheimer's trial, or is it just people who are at risk for developingAlzheimer's?Lotte Bjerre Knudsen (34:01):Yeah, no, you do not have to be obese. It's a standard Alzheimer's trial.GLP-1 PillsEric Topol (34:07):So this will be one of the really important trials to get a readout in people who are not having an obesity background. Now, the future, of course, gets us to oral GLP-1 drugs, which obviously you have there at Novo Nordisk. And it seems to me once that happens, if it can simulate the effects we see with the injectables, that would be another big step forward. What do you think about that?Lotte Bjerre Knudsen (34:39):Yeah. Isn't it interesting, what we've learned is that people actually don't mind the injections, right? Also, because I think it's simple, once a week injection and the needles are so small, obviously there are people who really have needle phobia, but take those aside, it's relatively few. I would argue if you close your eyes and somebody else used this needle on you, you would not be able to feel where it was inserted, right? They're so small. So it becomes maybe a personal preference. Would you like to have once a day or maybe twice a day tablets, or are you fine with once a week injection? And I think there probably will be quite a few once they've tried it. And now so many have tried it and they actually, maybe it gives us a simple lifestyle. You don't have to do it every day, right? You can just have a weekly reminder.Eric Topol (35:46):Yeah, no, I think that's really interesting what you're bringing up. I never thought we would evolve to a point where injectables were becoming some common, and I even have some physician colleagues that are taking three different injectable drugs.Lotte Bjerre Knudsen (36:00):That's also just mentioned Richard DiMarchi, who I shared the Breakthrough Prize with, and also Svetlana Mojsov, who I was one of the other two recipients for the Lasker prize because they both been at Rockefeller, and they both have worked a lot with peptides, and they both say the same thing. They were told so many times, this is not medicines, these kinds of molecules just they're not medicines. Forget about it. It turns out people were wrong. And peptides can be medicines, and they can even be produced also in a sustainable manner with fermentation, which is not a bad way of producing medicines. And people actually don't mind. Maybe some people actually even like it because it's once a week and then it's done.Confronting BarriersEric Topol (36:58):Yeah, no, that's a very important point. And the quest for the oral, which have more issues with bioavailability versus the peptides that are having such pronounced impact is really interesting to ponder. Well, before we wrap up, it's very clear the impact you've had has been profound, not just obviously at Novo Nordisk, but for the world of advancing health and medicine. And you've mentioned some of the key other people who have made seminal contributions, but I think you stand out because when we went deep into who took this field forward into obesity and who might also wind up being credited for Alzheimer's, it was you. And as a woman in science, especially in an era that you've been at Novo now for three and a half decades, there weren't many women in science leaders. And for one to be, as you said, you're brave for the good old boys to listen to the woman in science. Tell us about that challenge. Was this ever an issue in your career? Because obviously we want to have this whole landscape change. It is in the midst of change, but it's certainly still a ways to go. So maybe you can give us insight about that.Lotte Bjerre Knudsen (38:27):Yeah. Well, it for sure was a thing. It was a very male dominated world, and in a way, it might have prevented other people from doing it. But then, as I said, I was born brave for some reason. I'm not really sure why. It actually motivated me to kind of like, yeah, I'm going to show them. I'm going to show them. So it never really got to me that people, not everyone was nice to say. There was the first 10 years of my career, I think they were quite lonely, but then I was really inspired. I was so happy to be allowed to work on this. I thought it was super fun. And I did find people who wanted to play with me. And I also have to say that the CSO back then, Mads Krogsgaard Thomsen, he always supported me. So maybe I didn't get everything I wanted, but I always got what I needed in order to progress.(39:29):So on the women's side, and I think that yes, and there's still a change to be made, and I'm actually a little bit on behalf of my generation, maybe not too proud of the change we made because we didn't do a lot of change. It was all the women coming from the arts and the culture. They were the ones who actually make the big change here like 5 or 10 years ago. So I've also started to be more open about sharing my journey and advocating for women in science. So that's why I show up in pink to some of these award sessions just to be a little bit different and to maybe also just show that you don't have to be a certain type in order to fit into a certain job. But there is still a change to be made where people should be better at listening to what a person say and what ideas they say.(40:28):And they should be mindful about not always labeling women as passionate. When people call me passionate, I say like, no, thank you. I'm actually not too happy about the mother of either, because men always are being told. They're being told that they're brave and ambitious and courageous and strategic, whereas we we're, oh, you're so passionate. No, thank you. I'm also brave and strategic and ambitious and all of that. So we simply put different vocabulary on. I don't think people don't do it on purpose. I think we need to be better at actually giving people at work the same kind of vocabulary for their contributions. And I think that would mean that we get listened to in the same way. And that would be important. And then I also have to say that science, whether it comes from men or women, doesn't really matter.(41:32):Successful science is always the work of many. And I hope that some of you will actually listen to my last speech because that's what I speak about, how it's always the work of the many. And also, how if you want to do something novel, then you actually have to do it at a time when no one else is doing it, and you should believe in your ideas. So believe in it, listen to the critique, but believe in it, and then come back with new arguments or give up if you can't come up with any new arguments, right?Eric Topol (42:05):Well, we'll definitely put a link to the Lasker Awards speech that you gave. And I just want to say that the parallels here, for example, with Kati Karikó , my friend who had the Nobel Award for mRNA, she spent three decades trying to get people to listen to her and never got a grant from the NIH or other places [our conversation here]. And it was a really tough battle. And as you already touched on Svetlana Mojsov, who did some of the seminal work at Rockefeller to isolate the portion of GLP-1, that really was the key part peptide, and it was overlooked for years. And so, it's a tough fight, but you're paving the way here. And I think the contributions you've made are just so extraordinary. And I hope that over the years we will continue to see this momentum because people like what you've done, deserve this extraordinary recognition. I'm glad to see. And the Lasker Award is really capping off some of that great recognition that is so well deserved. We've covered a lot of ground today, and I want to make sure if I missed anything that you wanted to get into before we wrap up.Lotte Bjerre Knudsen (43:30):I think we've been around all the exciting biology of GLP-1, both in diabetes, obesity, cardiovascular, kidney, potential in Alzheimer's and addiction. We'll see, we need the clinical data and we've put out a message to inspire people to do new science. There's still a lot of unmet need out there. There's a lot of diseases that don't have good treatments. Even in the diseases we've talked about there's a lot of money for diabetes. There are no disease modifying therapies for diabetes. It's not really changing the course of the disease. So there's a lot of things that needs great scientists.Eric Topol (44:17):And I guess just in finishing the discovery of this class of drugs and what it's led to, tells us something about that, there's so much more to learn that is, this has taken on perhaps the greatest obstacle in medicine, which was could you safely treat obesity and have a marked effect. Which decades, many decades were devoted to that and gotten nowhere. It's like a breakthrough in another way is that here you have an ability to triumph over such a frustrating target, just like we've seen with Alzheimer's, of course, which may actually intersect with Alzheimer's, with a graveyard of failed drugs. And the ones that it were approved so far in certain countries, like the US are so questionable as to the safety and efficacy. But it gives us an inspiration about what is natural that can be built on the basic science that can lead to with people like you who push within the right direction, give the right nudges and get the support you need, who knows what else is out there that we're going to be discovering in the years ahead. It's a broad type of lesson for us.Lotte Bjerre Knudsen (45:38):Yeah, there is another hormone that's also in phase three clinical development, right? The amylin hormone. We've had pramlintide on the market for years, but we have this long-acting version that is in phase three clinical development. That could be the same kind of story because there's also additional biology on that one.Eric Topol (45:58):Yeah, this is what grabs me Lotte, because these gut hormone, we've known about them, and there's several more out there, of course. And look what they're having. They're not just gut hormones, like you said, they're neurotransmitters and they're body-wide receptors waiting to be activated, so it's wild. It's just wild. And I'm so glad to have had this conversation with you. Now, congratulations on all that you've done, and I know the Nature Medicine paper that just came out is going to be just one of many more to come in your career. So what a joy to have the chance to visit with you, and we'll be following the work that you and your colleagues are doing with great interest.Lotte Bjerre Knudsen (46:45):And thank you very much, and thank you for your wonderful podcast. They're really great to listen to on the go. Very easy listening.*****************************************Please complete the quick poll question above.Thank you for reading, listening and subscribing to Ground Truths.If you found this podcast informative please share it!All content on Ground Truths—its newsletters, analyses, and podcasts, are free, open-access.Paid subscriptions are voluntary and of course appreciated. All proceeds from them go to support Scripps Research. Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. I welcome all comments from paid subscribers and will do my best to respond to each of them and any questions.Thanks to my producer Jessica Nguyen and to Sinjun Balabanoff for audio and video support at Scripps Research.Ground Truths now has subscribers in 203 countries! Get full access to Ground Truths at erictopol.substack.com/subscribe

Send us a textDr. Sudip Parikh, Ph.D. ( https://www.aaas.org/person/sudip-parikh ), is the Chief Executive Officer of the American Association for the Advancement of Science (AAAS) and Executive Publisher of the Science family of journals and has spent the last two decades at the nexus of science, policy, and business.Prior to joining AAAS, Dr. Parikh was senior vice president and managing director at Drug Information Association (DIA Global), a neutral, multidisciplinary organization for healthcare product development where he led strategy in the Americas and oversaw DIA programs that catalyzed progress globally toward novel regulatory frameworks for advanced therapies.Prior to DIA, Dr. Parikh was a vice president at Battelle, a multibillion-dollar research and development organization, where he led two business units with over 500 scientific, technical, and computing experts performing basic and applied research, developing medicines and healthcare devices, developing agricultural products, and creating advanced analytics and artificial intelligence applications to improve human health.From 2001 to 2009, Dr. Parikh served as science advisor to the Republican leadership of the U.S. Senate Appropriations Committee, where he was responsible for negotiating budgets for the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Agency for Healthcare Research and Quality, Biomedical Advanced Research and Development Authority (BARDA), and other scientific and health agencies.As a key legislative liaison to the research and development ecosystem, Dr. Parikh was on the frontlines of many science policy issues debated during that time, including embryonic stem cell research, cloning, disease surveillance, bioterrorism, cyber security, and doubling the NIH budget.An active member of the scientific advocacy community, Dr. Parikh serves as a board member and officer for several impactful organizations, including Research!America ( https://www.researchamerica.org/ ), which he has chaired since 2023, Friends of Cancer Research, and ACT for NIH.  He also serves as co-chair of the Science and Technology Action Committee ( https://sciencetechaction.org/ ), Science CEO Group, and the Coalition for Trust in Health and Science ( https://trustinhealthandscience.org/ ).  He is also a member of the Board of Life Sciences of the U.S. National Academies of Science, Engineering, and Medicine.Dr. Parikh is an elected member of the American Academy of Arts and Sciences and the Council on Foreign Relations. He has also received multiple public service awards, including recognition from the Society for Women's Health Research, the American Association of Immunologists, the National AIDS Alliance, the Coalition for Health Services Research, and the Juvenile Diabetes Research Foundation.Early in his career, Dr. Parikh was a Presidential Management Intern at the NIH. He was awarded a National Science Foundation Graduate Research Fellowship while earning his Ph.D. in macromolecular structure and chemistry at the Scripps Research Institute in La Jolla, Calif.  There, he used structural biology and biochemistry techniques to probe the mechanisms of DNA repair enzymes.  Dr. Parikh completed undergraduate studies at the University of North Carolina at Chapel Hill, first as a journalism major before switching into materials science. #SudipParikh #AAAS #AmericanAssociationForTheAdvancementOfScience #Science #Policy #Business #DrugInformationAssociation #Battelle #ResearchAmerica  #ScienceAndTechnologyActionCommittee #CoalitionForTrustInHealthAndScience #Appropriations #Congress #ArtificialIntelligence #DrugDevelopment #ProgressPotentialAndPossibilitSupport the show

The Soil Matters with Dr. James White Season 2, Episode 40   Today's Guest: Dr. James White - Department of Plant Biology   James F. White is Professor of Plant Biology at Rutgers University in New Jersey where he and students conduct research on ecology of microbes that inhabit plants (endophytes). James White obtained the B.S. and M.S. degrees in Botany and Plant Pathology from Auburn University in Alabama, and the Ph.D. in Botany/Mycology from the University of Texas at Austin. James White is the author of more than 300 articles and book chapters, and author and editor of seven books on the biology of plant microbes, including Biotechnology of Acremonium Endophytes of Grasses (1994), Microbial Endophytes (2000), The Clavicipitalean Fungi (2004), The Fungal Community: Its Organization and Role in the Ecosystem (2005, 2017), Defensive Mutualism in Microbial Symbiosis (2009), and Seed Endophytes: Biology and Biotechnology (2019) and Microbial Inoculants and Other Microbiome Stimulants for Crops: Mechanisms and Applications (2021; Elsevier, In press). James White is an elected fellow of the American Association for the Advancement of Science (AAAS), and Associate Editor for journals Symbiosis, Fungal Ecology, MycoScience, Biology and Scientific Reports, and serves as Chief Editor for the Plant-Microbe Interactions Section of the MDPI journal Microorganisms. James White received the Alexopoulos Research Prize in 1996 (Mycological Society of America), the Distinguished Research Award in 1994 (Auburn University Montgomery), and the Research Excellence Award in 1998 (Rutgers University). James White has presented extensively at international industry and academic conferences focused on regenerative agriculture, plant biostimulants and crop microbiomes.   Your Host:   Leighton Morrison https://www.instagram.com/kingdomaqua... https://www.kingdomaquaponicsllc.com/   Executive Producer Ken Somerville https://www.instagram.com/kensomerville/ https://www.itsallaboutthebiology.ca Contact email itsallaboutthebiology@gmail.com Reach out to Ken for a quick 15 min call: https://calendly.com/kensomerville/connections   Help to support the mission: patreon.com/user?u=104510089   Discount codes available at: https://www.itsallaboutthebiology.ca/discountcodes   #flowers,#plants,#nature,#gardening,#garden,#growing,#koreannaturalfarming,#naturalfarming,#jadam,#naturalfertilizer,#naturalfarminginputs,#permaculture,#regenerative,#foodforest,#biodynamic,#bioactive,#organic,#notill,#knf,#organicgardening,#urbangardening,#containergardening,#homegardening,   Music by The Invisible Gardener (Andy Lopez) https://soundcloud.com/invisiblegardener For Full: Disclaimer

Gregg Braden is a five-time New York Times best-selling author, scientist, international educator and renowned as a pioneer in the emerging paradigm based in science, social policy and human potential. From 1979 to 1991 Gregg worked as a problem solver during times of crisis for Fortune 500 companies, including Cisco Systems, where he became the first Technical Operations Manager in 1991. He continues problem-solving today as his work reveals deep insights into the new human story, and how the discoveries inform the policies of everyday life and the emerging world. To date his research has led to 15 film credits and 12 award-winning books now published in over 40 languages Gregg is the proud recipient of numerous awards including The Walden Award for New Thought, The Illuminate Award for Conscious Visionaries and he is listed in the United Kingdom's Watkins Journal among the top 100 of “the world's most spiritually influential living people” for the 7th consecutive year. He is a nominee for the prestigious Templeton Award, established to honor “outstanding living individuals who have devoted their talents to expanding our vision of human purpose and ultimate reality.” Gregg is actively involved in visionary organizations and think tanks including the American Association for the Advancement of Science (AAAS), The Evolutionary Leadership Organization, The Laszlo Institute of New Paradigm Research and The Arlington Institute. He has presented his discoveries in over 30 countries on six continents and has been invited to speak to The United Nations, Fortune 500 companies and the U. S. military.

The Soil Matters with Dr. James White Season 2, Episode 17   Today's Guest: Dr. James White - Department of Plant Biology   James F. White is Professor of Plant Biology at Rutgers University in New Jersey where he and students conduct research on ecology of microbes that inhabit plants (endophytes). James White obtained the B.S. and M.S. degrees in Botany and Plant Pathology from Auburn University in Alabama, and the Ph.D. in Botany/Mycology from the University of Texas at Austin. James White is the author of more than 300 articles and book chapters, and author and editor of seven books on the biology of plant microbes, including Biotechnology of Acremonium Endophytes of Grasses (1994), Microbial Endophytes (2000), The Clavicipitalean Fungi (2004), The Fungal Community: Its Organization and Role in the Ecosystem (2005, 2017), Defensive Mutualism in Microbial Symbiosis (2009), and Seed Endophytes: Biology and Biotechnology (2019) and Microbial Inoculants and Other Microbiome Stimulants for Crops: Mechanisms and Applications (2021; Elsevier, In press). James White is an elected fellow of the American Association for the Advancement of Science (AAAS), and Associate Editor for journals Symbiosis, Fungal Ecology, MycoScience, Biology and Scientific Reports, and serves as Chief Editor for the Plant-Microbe Interactions Section of the MDPI journal Microorganisms. James White received the Alexopoulos Research Prize in 1996 (Mycological Society of America), the Distinguished Research Award in 1994 (Auburn University Montgomery), and the Research Excellence Award in 1998 (Rutgers University). James White has presented extensively at international industry and academic conferences focused on regenerative agriculture, plant biostimulants and crop microbiomes.   Your Host:   Leighton Morrison https://www.instagram.com/kingdomaqua... https://www.kingdomaquaponicsllc.com/   Executive Producer Ken Somerville https://www.instagram.com/kensomerville/ https://www.itsallaboutthebiology.ca Contact email itsallaboutthebiology@gmail.com Reach out to Ken for a quick 15 min call: https://calendly.com/kensomerville/connections   Help to support the mission: patreon.com/user?u=104510089   Discount codes available at: https://www.itsallaboutthebiology.ca/discountcodes   #flowers,#plants,#nature,#gardening,#garden,#growing,#koreannaturalfarming,#naturalfarming,#jadam,#naturalfertilizer,#naturalfarminginputs,#permaculture,#regenerative,#foodforest,#biodynamic,#bioactive,#organic,#notill,#knf,#organicgardening,#urbangardening,#containergardening,#homegardening,   Music by The Invisible Gardener (Andy Lopez) https://soundcloud.com/invisiblegardener For Full: Disclaimer

Gregg Braden is a five-time New York Times best-selling author, scientist, educator, and pioneer in the emerging paradigm bridging science, social policy, and human potential.From 1979 to 1991, Gregg worked as a problem solver during times of crisis for Fortune 500 companies.He continues problem-solving today as his work reveals deep insights into the new human story and how the discoveries inform the policies of everyday life and the emerging world.His research resulted in the 2003 discovery of intelligent information encoded into the human genome and the 2010 application of fractal time to predict future occurrences of past events. Gregg's work has led to 15 film credits, 12 award-winning books now published in over 40 languages, and numerous awards, including Walden Award for New Thought, the Illuminate Award for Conscious Visionaries, and Gregg is listed on the United Kingdom's Watkins Journal among the top 100 of “the world's most spiritually influential living people” for the 7th consecutive year. He was a 2020 nominee for the prestigious Templeton Award, established to honor “outstanding living individuals who have devoted their talents to expanding our vision of human purpose and ultimate reality.”He has presented his discoveries in over 34 countries on six continents and has been invited to speak to The United Nations, Fortune 500 companies, and the U.S. military.Gregg is a member of scientific and visionary organizations, including the American Association for the Advancement of Science (AAAS), the Laszlo Institute of New Paradigm Research, the Institute of HeartMath's Global Coherence Initiative, the Source of Synergy Evolutionary Leadership Circle and The Arlington Institute, as well as an original signatory of the 2017 Fuji Declaration, the international call to collectively catalyze a timely shift in the course of human history.Please enjoy my conversation with Gregg Braden.Become a supporter of this podcast: https://www.spreaker.com/podcast/next-level-soul-podcast-with-alex-ferrari--4858435/support.

Dr. Matt Kaeberlein is the Chief Executive Officer at Optispan, Inc., Affiliate Professor of Oral Health Sciences at the University of Washington, and Co-Director of the Dog Aging Project. Dr. Kaeberlein's research interests are focused on understanding the biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve the quality of life for people and companion animals. He is a Fellow of the American Association for the Advancement of Science (AAAS), the American Aging Association (AGE), and the Gerontological Society of America (GSA). Dr. Kaeberlein has published more than 250 peer-reviewed papers in the field of longevity and has received several prestigious awards including young investigator awards from the Ellison Medical Foundation and the Alzheimer's Association, the Vincent Cristofalo Rising Star in Aging Research Award, the Murdock Trust Award, the NIA Nathan W. Shock Award, and the Robert W. Kleemeier Award for outstanding research in the field of gerontology. Dr. Kaeberlein is the founding Director of the University of Washington Healthy Aging and Longevity Research Institute, former Director of the NIH Nathan Shock Center of Excellence in the Basic Biology of Aging and the Biological Mechanisms of Healthy Aging Training Program at the University of Washington, and former CEO and Chair of the American Aging Association.

Hi everyone. Did you know there are a wealth of opportunities out there for those who want to start businesses? But opportunities in startups don't just apply to entrepreneurs! Lots of others can be a part of this boom, too. My guest expert, Bill Provine, the CEO of an organization devoted to helping startups get off the ground, shares his expertise about this and much more on today's episode. Among other things, Bill speaks about (1) the many different kinds of startup ventures his organization, Innovation Space, assists, (2) some major trends taking place in the world of entrepreneurship today, (3) contrasts in the approach to entrepreneurship around the globe, and (4) tools to help those who are launching or looking to grow their ventures. True to our focus here on Looking Forward®, Bill lays out a boatload of opportunities for those interested in being part of the start-up world. Many of these involve positions or roles that go well beyond the company founder or visionary, too. Finally, Bill takes a look at how the rest of this decade looks for startup opportunities, and he provides numerous tips for those interested in this field of endeavor. Now a bit about Bill. Bill Provine is the founder, President, and Chief Executive Officer of the Innovation Space, in addition to a member of its Board of Directors. In this role, Bill oversees all operations and is responsible for its overall performance. Prior to joining the Innovation Space, Bill worked for DuPont. There he led global operations for science and engineering, encompassing DuPont's open innovation practice. This included oversight for DuPont's innovation centers and regional laboratories around the world. He also has served in a variety of research, marketing, business development, joint venture, and manufacturing leadership roles in DuPont over the last 30 years.Bill is very active in cultivating and advancing science across sectors and has served on numerous private company, university, industrial, governmental, and scientific association advisory and management boards and committees. He currently serves on the board of the American Association for the Advancement of Science (AAAS) supporting scientific research and advocacy; the Resolution Project, supporting social entrepreneurship; and the National Advisory Council on Innovation and Entrepreneurship with the U.S. Department of Commerce, supporting creation of a national entrepreneurship strategy.Now a few words about a special deal you can get just by being a Looking Forward® listener!Do you make podcasts, video courses, or other content? That means you need your own engaging website and mobile app for everything you make… and SupaPass can help. Turn your followers into super fans and paid customers. Elevate your brand with your own stunning website and mobile app. And with SupaPass it's never been easier. SupaPass is the most powerful content app maker on the market and NOW you can try it for free. Or like me, you can be on one of their other plans. In fact, enter code LOOKINGFORWARD and get a 10% lifetime discount on any of their plans. Go to SupaPass.com I invite you to LISTEN, ENJOY, LEARN, LIKE, COMMENT, and SHARE this episode! NOTE: We may include your comment with attribution, of course, on our website. And please subscribe to Looking Forward®: Opportunities for Job, Career, Business, and Investment Seekers, too! If you are interested in sponsoring 3 episodes of Looking Forward-- or distributing our content-- please let us know. (Give a listen to what I have to say about SupaPass. We can do...

This is part two of our three part series with Dr. Matt Kaeberlein. Dr. Matt Kaeberlein is the Chief Executive Officer at Optispan, Inc., Affiliate Professor of Oral Health Sciences at the University of Washington, and Co-Director of the Dog Aging Project. Dr. Kaeberlein's research interests are focused on understanding biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life for people and companion animals.He is a Fellow of the American Association for the Advancement of Science (AAAS), the American Aging Association (AGE), and the Gerontological Society of America (GSA). Dr. Kaeberlein has published more than 250 scientific papers in the field of aging biology and has received several prestigious awards including young investigator awards from the Ellison Medical Foundation and the Alzheimer's Association, the Vincent Cristofalo Rising Star in Aging Research Award, the Murdock Trust Award, the NIA Nathan W. Shock Award, and the Robert W. Kleemeier Award for outstanding research in the field of gerontology.Dr. Kaeberlein is the founding Director of the University of Washington Healthy Aging and Longevity Research Institute, former Director of the NIH Nathan Shock Center of Excellence in the Basic Biology of Aging and the Biological Mechanisms of Healthy Aging Training Program at the University of Washington, and former CEO and Chair of the American Aging Association.You can also watch the original interview on the Optispan Youtube Channel HEREPrime Health Associates

Here's how you spiritually navigate through challenging times. Hint: being your You-est You and honoring your gifts, talents, and life is more important than you might think!    As always, take what you like from this conversation and leave whatever might not resonate. I'm honored to be part of your podcast playlist and appreciate being on your life journey with you.   Key Takeaways:

Dr. Matt Kaeberlein is the Chief Executive Officer at Optispan, Inc., Affiliate Professor of Oral Health Sciences at the University of Washington, and Co-Director of the Dog Aging Project. Dr. Kaeberlein's research interests are focused on understanding biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life for people and companion animals. He is a Fellow of the American Association for the Advancement of Science (AAAS), the American Aging Association (AGE), and the Gerontological Society of America (GSA). Dr. Kaeberlein has published more than 250 scientific papers in the field of aging biology and has received several prestigious awards including young investigator awards from the Ellison Medical Foundation and the Alzheimer's Association, the Vincent Cristofalo Rising Star in Aging Research Award, the Murdock Trust Award, the NIA Nathan W. Shock Award, and the Robert W. Kleemeier Award for outstanding research in the field of gerontology. Dr. Kaeberlein is the founding Director of the University of Washington Healthy Aging and Longevity Research Institute, former Director of the NIH Nathan Shock Center of Excellence in the Basic Biology of Aging and the Biological Mechanisms of Healthy Aging Training Program at the University of Washington, and former CEO and Chair of the American Aging Association.You can also watch the original interview on the Optispan Youtube Channel HEREPrime Health Associates

Dr. Gary Null read his letter to Science/AAAS

Today your detectives of the demented take a stroll down history lane to the happenings of one of the most notorious serial killers in history, his head count questionable, his identity unknown but the savagery of his crimes undoubtable. Join us as the something perplexing podcast looks at Jack the Ripper! = Something_Perplexing_Podcast (@something_perplexing_podcast) • Instagram photos and videos Francis Tumblety - Wikipedia 5 Reasons Why Vincent van Gogh was Jack the Ripper | Van gogh, Gogh, Van gogh irises (pinterest.com) 5 Reasons Why Vincent van Gogh was Jack the Ripper (buzzfeed.com) The UnXplained: Jack the Ripper's Secret Identity Revealed (Season 3) (youtube.com) Possible Early Victims of Jack the Ripper. (jack-the-ripper.org) Jack the Ripper - Wikipedia Does a new genetic analysis finally reveal the identity of Jack the Ripper? | Science | AAAS

Gregg Braden is a five-time New York Times best-selling author, researcher, educator, lecturer and internationally renowned as a pioneer bridging science, spirituality, and human potential.From 1979 to 1991 Gregg worked as a problem solver during times of crisis for Fortune 500 companies, including Cisco Systems where he became the first Technical Operations Manager in 1991.He continues problem-solving today as he merges modern science and the wisdom of our past to reveal real-world solutions to the issues that challenge our lives. His research has led to 15 film credits and 12 award-winning books now published in over 40 languages.Gregg is a member of the American Association for the Advancement of Science (AAAS) and is active with visionary organizations including the HeartMath Global Coherence Initiative and The Arlington Institute. He has presented his discoveries in over 30 countries on six continents and has been invited to speak to The United Nations, Fortune 500 companies and the U. S. military.The United Kingdom's Watkins Journal lists Gregg among the top 100 of “the world's most spiritually influential living people” for the 7th consecutive year, and he is a 2020 nominee for the prestigious Templeton Award, established to honor “outstanding individuals who have devoted their talents to expanding our vision of human purpose and ultimate reality.”Please enjoy my conversation with Gregg Braden.

Sanyin Siang is Derek's amazing featured guest this week! Sanyin shares highlights from her journey, and how to accept positive affirmations and constructive criticism as data points in your life, importance of being generous, and how to be vulnerable.Sanyin helps leaders launch and create value by focusing on mindset, behavioral change, and team and culture building. Sanyin is a CEO Coach, Advisor, Author,the Executive Director of Duke University's Fuqua/Coach K Center on Leadership & Ethics (COLE) and a Professor with its Pratt School of Engineering.The COLE center is a leadership laboratory that engages all of Duke's Daytime MBA students and convenes high-level think tank gatherings to explore today's complex leadership opportunities and challenges.Sanyin coaches C-suite executives and is in the original cohort of Marshall Goldsmith's 100 Coaches. She is an advisor for GV (former Google Ventures), Duke Corporate Education, and the Sports Innovation Lab. Her thought leadership has appeared in Forbes, Fortune, The Wall Street Journal, and CNN. She has more than 1 million LinkedIn followers. She is a LinkedIn 2017 & 2018 Top 10 Influencer and a 2018 Thinkers50 On the Radar.Sanyin's board service has included those of The Emily K Center, The Museum of Life & Science, Duke Children's Hospital & Health Center. She is a Sr. Advisor with Dan Ariely's Center for Advanced Hindsight and a faculty with StoryLab at Duke. She has spoken to audiences from the White House to Global Sports Management and Owners Summits.Prior to Duke, Sanyin worked at the American Association for the Advancement of Science (AAAS), the world's largest federation of scientific and engineering societies, and publisher of Science. Her initiatives explored the ethical, social, and legal implications of technological advances before they became reality.Her book The Launch Book: Motivational Stories for Launching Your Idea, Business, or Next Career, uses behavioral science principles to help readers build the mindset for addressing major change.Sanyin received a BSE in Biomedical Engineering and an MBA from Duke University.Order "The Launch Book": https://www.amazon.com/gp/product/B074JC5L9V/ref=dbs_a_def_rwt_bibl_vppi_i0

Award-winning dementia researcher and educator Dr. Nir Grossman joins Being Patient Live Talks to talk about the potential of cutting-edge medical technology like deep brain stimulation as an emerging approach to treating neurodegenerative diseases like Alzheimer's. Grossman is an associate professor at the Department of Brain Sciences at Imperial College London and a founding fellow of the UK Dementia Research Institute (UK-DRI). He received a prestigious prize from the Science Journal and American Association for the Advancement of Science (AAAS) for developing a new, non-invasive method of deep brain stimulation, called temporal interference, which is now in early clinical trials. Previously, this procedure required invasive brain surgery. His research has been published in scientific journals like Cell, Science, and Nature Neuroscience. Read the article here: https://www.beingpatient.com/nir-grossman-deep-brain-stimulation-dementia/ ___ If you loved watching this Live Talk, visit our website to find more of our Alzheimer's coverage and subscribe to our newsletter: https://www.beingpatient.com/ Follow Being Patient: Twitter: https://twitter.com/Being_Patient_ Instagram: https://www.instagram.com/beingpatientvoices/ Facebook: https://www.facebook.com/beingpatientalzheimers LinkedIn: https://www.linkedin.com/company/being-patient Being Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia. Check out our latest Live Talks: https://www.beingpatient.com/category/video/ #DeepBrainStimulation #Neuromodulation #AlzheimersResearch #Dementia #Alzheimers

Award-winning dementia researcher and educator Dr. Nir Grossman joins Being Patient Live Talks to talk about the potential of cutting-edge medical technology like deep brain stimulation as an emerging approach to treating neurodegenerative diseases like Alzheimer's. Grossman is an associate professor at the Department of Brain Sciences at Imperial College London and a founding fellow of the UK Dementia Research Institute (UK-DRI). He received a prestigious prize from the Science Journal and American Association for the Advancement of Science (AAAS) for developing a new, non-invasive method of deep brain stimulation, called temporal interference, which is now in early clinical trials. Previously, this procedure required invasive brain surgery. His research has been published in scientific journals like Cell, Science, and Nature Neuroscience. Read the article here: https://www.beingpatient.com/nir-grossman-deep-brain-stimulation-dementia/ ___ If you loved watching this Live Talk, visit our website to find more of our Alzheimer's coverage and subscribe to our newsletter: https://www.beingpatient.com/ Follow Being Patient: Twitter: https://twitter.com/Being_Patient_ Instagram: https://www.instagram.com/beingpatientvoices/ Facebook: https://www.facebook.com/beingpatientalzheimers LinkedIn: https://www.linkedin.com/company/being-patient Being Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia. Check out our latest Live Talks: https://www.beingpatient.com/category/video/ #DeepBrainStimulation #Neuromodulation #AlzheimersResearch #Dementia #Alzheimers

In this episode, we speak with Dr Travis York, the Director of Inclusive STEMM Ecosystems for Equity and Diversity (ISEED) at the American Association for the Advancement of Science (AAAS). We begin our conversation exploring how Dr York first became interested in higher education. After discussing his educational journey via Geneva College, Oxford University, and Penn State, we then discuss his exceptional work in transforming the STEM landscape to be more equitable, diverse, inclusive, and accessible to all. Episode transcript available here: https://www.herroyalscience.com/post/43-access

Welcome to The You-est You™ podcast, where we explore the depths of human potential and the power of spirituality. In today's episode, we have the privilege of delving into the realms of consciousness, divinity, and the unlimited possibilities that lie within each of us. Today's guest is my mentor and dear friend, Gregg Braden, a pioneer in bridging the worlds of science and spirituality. Gregg's work has illuminated the path to unlocking our true potential and reconnecting with our innate divinity, transcending perceived human limits.   Episode Highlights:   *Defining Divinity Beyond Religion: Gregg Braden reminds us that divinity transcends the boundaries of religion. It's not about dogma; it's about recognizing the sacred essence within ourselves. When we tap into our divinity, we access a wellspring of power and potentiality often shrouded by fear and doubt.   *Consciousness as the Fertile Ground: Gregg explores the idea that consciousness is the fertile field in which our reality takes root. By nurturing our consciousness, we unlock the gateway to our divine potential. This is where our imagination, creativity, and intuition flourish.   *The World Speaking to Us: Are we truly listening to the world around us? Gregg highlights the convergence of science and consciousness, revealing how they are coming together in profound ways. This convergence invites us to pay closer attention to the subtle messages and interconnectedness of our world.   *A Time of Transformation: We're living in a time of unprecedented change, marked by social upheaval, climate challenges, and conflicts. Gregg emphasizes that this is not "business as usual." It's a pivotal moment where everything is being uprooted, presenting an opportunity for positive transformation.   *The Power of Beauty: Beauty holds a unique power—it creates coherence. Gregg reminds us that we are highly advanced soft technology, and we have the ability to self-regulate through our thoughts, breath, and emotions. Striving to see beauty in all things can be a powerful catalyst for positive change.   In this enlightening conversation with Gregg Braden, we've explored the concept of divinity as a universal essence that transcends religious boundaries. By tapping into our divinity and nurturing our consciousness, we unlock our potential for creativity, intuition, and transformation. We're reminded that the world is speaking to us, urging us to pay attention and embrace positive change in these times of extremes. As we strive to see beauty in all things, we harness the power to create coherence in our lives and in the world around us.   Thank you for joining us on this journey of self-discovery and spiritual awakening. If you found this episode inspiring, please share it with someone who might benefit from these profound insights. And as always, stay tuned for more enlightening conversations on The You-est You™ podcast!   More about Gregg Braden:   Gregg Braden is a five-time New York Times best-selling author, scientist, and international educator and is renowned as a pioneer in the emerging paradigm based on science, social policy, and human potential. From 1979 to 1991, Gregg worked as a problem solver during times of crisis for Fortune 500 companies, including Cisco Systems, where he became the first Technical Operations Manager in 1991. He continues problem-solving today as his work reveals deep insights into the new human story and how the discoveries inform the policies of everyday life and the emerging world. To date, his research has led to 15 film credits and 12 award-winning books now published in over 40 languages.   Gregg is the proud recipient of numerous awards, including The Walden Award for New Thought, The Illuminate Award for Conscious Visionaries, and he is listed in the United Kingdom's Watkins Journal among the top 100 of “the world's most spiritually influential living people” for the 7th consecutive year.    He is a nominee for the prestigious Templeton Award, established to honor “outstanding living individuals who have devoted their talents to expanding our vision of human purpose and ultimate reality.” Gregg is actively involved in visionary organizations and think tanks, including the American Association for the Advancement of Science (AAAS), The Evolutionary Leadership Organization, The Laszlo Institute of New Paradigm Research, and The Arlington Institute. He has presented his discoveries in over 30 countries on six continents and has been invited to speak to The United Nations, Fortune 500 companies, and the U. S. military.     A Free Toolset To Design Your Best Life This stunning free toolset is a 7-day workbook (25 pages full) of powerful mindset practices, grounding meditations (and audio), a new beautiful time management system and template to set your personalized schedule for your best productivity, a personalized energy assessment, and so much more. It was designed to specifically help you uplevel your routine and self-care habits for success so you can radiate and become your ‘You-est You'. These tools are some of Julie's best practices used with hundreds of her clients to help you feel more confident, clear, and connected to your best self so that you feel inspired to take on the world. Get it at: juliereisler.com/toolset     Looking To Help Others Get Unstuck and Design Their Best Life? If you are feeling a strong urge to help other big-hearted empaths get unstuck and design their best life, you've got to check out my Life Designer Coach Academy. This world-class four-month virtual live coach certification program will give you proven tools, techniques, practices, and methodology to be a powerful coach. This coaching program is for aspiring and current coaches looking to fill in the missing pieces and gain confidence and mastery both in the coaching core competencies and the integrative health modalities from a mind-body science, positive psychology, and healing arts perspective. To learn more, go to lifedesignercoachacademy.com.   You-est You Intention Cards Want your own powerful deck of 33 You-est You Intention Cards? These cards were channeled by Julie. Each card has an empowering intention and deeper questions to ask your ‘You-est You' for greater self-awareness, higher consciousness, and spiritual growth. You can get them now at juliereisler.com/shop.    Sacred Connection This community is a sacred, safe place built on love and acceptance. It was created to help you evolve and expand into your highest self. Please share your wisdom, comments, and thoughts. I love hearing from you and learning how you are being your truest, you-est you. Please join us in our Facebook group: The You-est You® Podcast Community. Join host Julie Reisler, author and multi-time TEDx speaker, each week to learn how you can tap into your best self and become your You-est You® to achieve inner peace, happiness, and success at a deeper level! Tune in to hear powerful, inspirational stories and expert insights from entrepreneurs, industry thought leaders, and extraordinary human beings that will help to transform your life. Julie also shares a-ha moments that have shaped her life and career and discusses key concepts from her book Get a PhD in YOU. And as always, if you're enjoying this podcast, thank you for taking a moment to rate, review and love up on it by sharing it with others you love. It helps make these conversations available to more amazing people around the globe. Here's to your being your ‘You-est You!' Enjoying the show? For iTunes listeners, get automatic downloads and share the love by subscribing, rating & reviewing here! I can't thank you enough for your support, kindness, and good juju.   *Share what you are struggling with or looking to transform with Julie at team@juliereisler.com. Julie would love to start covering topics of the highest interest to YOU.   You-est You Links: Subscribe to the Podcast  Learn more at JulieReisler.com Become a certified Life Coach in Julie's Life Designer® Coach Academy certification program Get carefully curated sacred resources for spiritually oriented coaches, creatives & healers in the Sacredology® Vault Get a Free Toolset to Design Your Best Life Join The You-est You® Podcast Community on Facebook Subscribe to Julie's YouTube Channel Book Julie as a speaker at your upcoming event Amazon #1 Best selling book Get a PhD in YOU Download free guided meditations from Insight Timer Julie's Hungry For More Online Program (10-Module Interactive Course) 15 Days Of Gratitude To Change Your Life on Insight Timer Take the Free Intuition Quiz To Find Out Your Unique Superpower  

Here Prof Kaeberlein talks about where he sees longevity going in the near future. We also talk about personalized medicine and whether it is ready for general use. Dr. Kaeberlein's research interests are focused on biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life. He has published more than 200 scientific papers, has been recognized by several prestigious awards, and has Fellow status in the American Association for the Advancement of Science (AAAS), the American Aging Association, and the Gerontological Society of America (GSA). Dr. Kaeberlein is currently the CEO of the American Aging Association and has served on the Board of Directors for the Federation of American Societies for Experimental Biology (FASEB), AGE, and GSA. Dr. Kaeberlein is the founding Director of the UW Healthy Aging and Longevity Research Institute, the Director of the UW Nathan Shock Center of Excellence in the Basic Biology of Aging, Director of the Biological Mechanisms of Healthy Aging Training Program, and founder and co-Director of the Dog Aging Project.

Here Prof Kaeberlein discusses his thoughts on exercise and diet. In particular he goes into detail on intermittent fasting, time restricted feeding and calorie restriction. Dr. Kaeberlein's research interests are focused on biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life. He has published more than 200 scientific papers, has been recognized by several prestigious awards, and has Fellow status in the American Association for the Advancement of Science (AAAS), the American Aging Association, and the Gerontological Society of America (GSA). Dr. Kaeberlein is currently the CEO of the American Aging Association and has served on the Board of Directors for the Federation of American Societies for Experimental Biology (FASEB), AGE, and GSA. Dr. Kaeberlein is the founding Director of the UW Healthy Aging and Longevity Research Institute, the Director of the UW Nathan Shock Center of Excellence in the Basic Biology of Aging, Director of the Biological Mechanisms of Healthy Aging Training Program, and founder and co-Director of the Dog Aging Project.

Here Prof Kaeberlein talks about the million molecule challenge and why he thought that it was necessary. Dr. Kaeberlein's research interests are focused on biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life. He has published more than 200 scientific papers, has been recognized by several prestigious awards, and has Fellow status in the American Association for the Advancement of Science (AAAS), the American Aging Association, and the Gerontological Society of America (GSA). Dr. Kaeberlein is currently the CEO of the American Aging Association and has served on the Board of Directors for the Federation of American Societies for Experimental Biology (FASEB), AGE, and GSA. Dr. Kaeberlein is the founding Director of the UW Healthy Aging and Longevity Research Institute, the Director of the UW Nathan Shock Center of Excellence in the Basic Biology of Aging, Director of the Biological Mechanisms of Healthy Aging Training Program, and founder and co-Director of the Dog Aging Project.

Here Prof Kaeberlein talks about the Dog Aging Project a study which is following 100,000's of dogs to understand aging better and includes a RTC of rapamycin related to lifespan. Dr. Kaeberlein's research interests are focused on biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life. He has published more than 200 scientific papers, has been recognized by several prestigious awards, and has Fellow status in the American Association for the Advancement of Science (AAAS), the American Aging Association, and the Gerontological Society of America (GSA). Dr. Kaeberlein is currently the CEO of the American Aging Association and has served on the Board of Directors for the Federation of American Societies for Experimental Biology (FASEB), AGE, and GSA. Dr. Kaeberlein is the founding Director of the UW Healthy Aging and Longevity Research Institute, the Director of the UW Nathan Shock Center of Excellence in the Basic Biology of Aging, Director of the Biological Mechanisms of Healthy Aging Training Program, and founder and co-Director of the Dog Aging Project.

In a thought-provoking conversation with Gregg Braden, we delve into the transformative concept of "Connecting Heart and Mind." Braden emphasises the heart's unique neural network, enabling us to transcend judgments and polarities. He shares personal experiences highlighting the heart's healing power and introduces heart-brain coherence through simple practices that enhance well-being and resilience. The Beauty Prayer, inspired by Navajo tradition, encourages us to embrace beauty as a guiding force in our lives. Braden also calls on us to acknowledge our innate divinity, offering a path to overcome external fears. Amidst global challenges, he urges us to focus on personal growth and conscious choices, presenting a roadmap to navigate our ever-changing world. This podcast interview empowers us to approach life with grace and unwavering resilience, uniting heart, and mind for a brighter future. About Gregg Braden Gregg Braden is a five-time New York Times best-selling author, scientist, international educator and renowned as a pioneer in the emerging paradigm based in science, social policy and human potential. From 1979 to 1991 Gregg worked as a problem solver during times of crisis for Fortune 500 companies, including Cisco Systems, where he became the first Technical Operations Manager in 1991. He continues problem-solving today as his work reveals deep insights into the new human story, and how the discoveries inform the policies of everyday life and the emerging world. To date his research has led to 15 film credits and 12 award-winning books now published in over 40 languages. Gregg is the proud recipient of numerous awards including The Walden Award for New Thought, The Illuminate Award for Conscious Visionaries and he is listed in the United Kingdom's Watkins Journal among the top 100 of “the world's most spiritually influential living people” for the 7th consecutive year. He is a nominee for the prestigious Templeton Award, established to honor “outstanding living individuals who have devoted their talents to expanding our vision of human purpose and ultimate reality.” Gregg is actively involved in visionary organizations and think tanks including the American Association for the Advancement of Science (AAAS), The Evolutionary Leadership Organization, The Laszlo Institute of New Paradigm Research and The Arlington Institute. He has presented his discoveries in over 30 countries on six continents and has been invited to speak to The United Nations, Fortune 500 companies and the U. S. military. You can watch the video of the interview on YouTube Videos on Heart Coherence by Gregg Braden These Powerful Methods Will Build the Bridge Between the Heart & the Brain Two Powerful Methods to Awaken Hear & Brain Connection Three Keys to Heart - Brain - Earth - Harmony Find Out More About Gregg Braden Visit Gregg Braden's Website Connect with Gregg Braden on Facebook Follow Gregg Braden on Instagram @Gregg.Braden Watch Gregg's Amazing YouTube Channel

Tremenda conversación. Wao, la verdad que aprender de como funcionan las cosas políticas en las ciencias es excesivamente importante para poder hacer ciencia. Aquí el gran J. Alvelo nos explica lo que implica hacer ciencia, como recibir fondos y lo que se puede hacer para aprender mas sobre esto. También tocamos el tema de las vacunas, los virus y la manera de ver la comunicación científica de una manera objetiva, como que se esta haciendo y que se tiene que hacer. The climate is changing. Engineering education needs to change as well - Martin - 2022 - Journal of Engineering Education - Wiley Online Library Navigating the New Arctic and the UN Ocean Decade: Ingenta Connect Jesus Alvelo (@MinistroCiencia) / X (twitter.com)California Policy Actions for Pandemic Preparation, Response, and Recovery - California Council on Science & Technology (CCST)Jesus Alvelo: AAAS Policy Fellow Turns from Bacteria to Budgets | American Association for the Advancement of Science (AAAS)curiosidad científica podcast(curiosidadcientificapodcast) - Official - LinktreeCuriosidad cientifica podcast (@curiosidadcitfk) / X (twitter.com)vale.alva (@curiosidacientificapodcast) • Instagram photos and videos --- Support this podcast: https://podcasters.spotify.com/pod/show/agustin-valenzuela/support

This episode is brought to you by Rupa Health, Sensate, ButcherBox, and Thrive Market.We're in the midst of a psychedelic renaissance. Compounds that have long been considered recreational drugs by conventional standards are finally being recognized through science as powerful tools for overcoming hard-to-treat health issues like PTSD, depression, addiction, and more. Today on The Doctor's Farmacy, I'm excited to talk to my good friend and one of the world's most renowned mycologists, Paul Stamets, all about psilocybin and how this compound is helping us reimagine our way of treating one of the most important public health crises today—mental illness. Paul Stamets is a speaker, author, mycologist, medical researcher, and entrepreneur and is considered an intellectual and industry leader in fungi: habitat, medicinal use, and production. His breakthrough research has created a paradigm shift for helping ecosystems worldwide. He has received numerous awards, including Invention Ambassador for the American Association for the Advancement of Science (AAAS), the National Mycologist Award from the North American Mycological Association (NAMA), and the Gordon & Tina Wasson Award from the Mycological Society of America (MSA). In 2020, Paul was inducted into the Explorer's Club. He has been awarded myriad patents in the field of mycology. Paul is the founder and sole owner of Fungi Perfecti, LLC, the maker, and marketer of the category-leading myco-supplement Host Defense line.This episode is brought to you by Rupa Health, Sensate, ButcherBox, and Thrive Market.Access more than 3,000 specialty lab tests with Rupa Health. You can check out a free, live demo with a Q&A or create an account at RupaHealth.com today.Head on over to getsensate.com/Farmacy and use code FARMACY to get 10% off your Sensate device today.For new members of ButcherBox, you can receive New York strip steaks for a year PLUS $20 off your first order. Go to ButcherBox.com/farmacy and use code FARMACY.Thrive Market is offering 30% off your first order and a free gift of up to $60 if you sign up now! Head over to thrivemarket.com/Hyman today.Here are more details from our interview (audio version / Apple Subscriber version):Why we should care about mushrooms (6:50 / 4:39)Why mushrooms are the zeitgeist of our time (12:35 / 10:00) Health benefits of mushrooms (13:54 / 12:07) How psilocybin works in human brains (29:34 / 25:48) Psilocybin as treatment for mental health and addiction (33:07 / 28:55) Specific psilocybin molecules that influence us neurologically (40:04 / 35:46)Research on psilocybin for mental health issues (51:58 / 48:06)The Stamets Stack microdosing method (1:02:41 / 58:57)The future of psilocybin use in our society (1:15:43 / 1:11:50) A day in the life of Paul Stamets (1:20:16 / 1:16:22) Learn more at paulstamets.com. Hosted on Acast. See acast.com/privacy for more information.

In this episode we explore our understanding of longevity with a leading longevity researcher. Guest:   Dr Matt Kaeberlein, PhD Former Director, Healthy Aging and Longevity Research Institute Former Director, Biological Mechanisms of Healthy Aging Training Program Co-Director, UW Nathan Shock Center of Excellence in the Basic Biology of Aging Co-Director, Dog Aging Project Professor of Pathology Adjunct Professor of Genome Sciences Adjunct Professor of Oral Health Sciences   Dr. Kaeberlein's research interests are focused on biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life. He has published more than 200 scientific papers, has been recognized by several prestigious awards, and has Fellow status in the American Association for the Advancement of Science (AAAS), the American Aging Association, and the Gerontological Society of America (GSA).  Dr. Kaeberlein is currently the CEO of the American Aging Association and has served on the Board of Directors for the Federation of American Societies for Experimental Biology (FASEB), AGE, and GSA. Dr. Kaeberlein is the founding Director of the UW Healthy Aging and Longevity Research Institute, the Director of the UW Nathan Shock Center of Excellence in the Basic Biology of Aging, Former Director of the Biological Mechanisms of Healthy Aging Training Program, and founder and co-Director of the Dog Aging Project.   Recommended Resources:   Twitter @mkaeberlein   Peter Attia: Podcast, book, articles  

Welcome to part 1 of episode 33 on the “Love at First Science'' Podcast where Dr. Ben Rein speaks into science behind Psychedelics, including the current research on its mechanisms in the body and how it affects behavior. Do you want to learn more about empathy and the effect of psychedelics? Dr. Ben Rein is a researcher in the field of neuroscience and besides that he is also a creator of educational science videos on tiktok and Instagram. He shares how he wants to make science more accessible through his videos and  how to make reading scientific papers easier. On the podcast he talks about the connection between neuroscience and practicing yoga. He presents his concept of “a little bit more”, which is ultimately the secret to keeping your brain young forever. In addition, he explains how aging affects the brain and how healthy and powerful social interactions are to keep a healthy brain. We also venture into the therapeutic value of psychedelics,  the research behind them and what parts of the brain are affected by these controversial drugs. We also touch on the power of sleep, autism, and social media.  --------------------------------------------------------------------------------   Learn More About Dr. Ben Rein: Ben Rein, Ph.D. is a postdoctoral researcher at Stanford University. In his current research, Ben is investigating the neural basis of empathy, and how empathic behaviors can be enhanced. He received his PhD in neuroscience from SUNY Buffalo, earning the Dean's Award for Outstanding Dissertation Research. Ben's thesis focused on autism spectrum disorder and identified key systems in the brain that regulate social behaviors. Outside of the lab, Ben creates educational science videos for an audience of more than 900,000 followers on TikTok, Instagram and BiliBili. In his videos, he summarizes recent research papers, teaches fundamental neuroscience principles, and debunks "viral" videos containing scientific misinformation. Ben's science communication has been recognized with awards from Stanford University, the American Association for the Advancement of Science (AAAS), and the Mind Science Foundation.  --------------------------------------------------------------------------------   Check out & learn more with Dr. Ben Rein: ⁠Dr. Ben Rein's Website⁠ ⁠⁠Dr. Ben Rein's Youtube⁠ ⁠⁠Dr. Ben Rein's Instagram⁠ --------------------------------------------------------------------------------  My Socials:   ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Celest's Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Celest's Website ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Too Flexible To Feel Good Book

Welcome to part 1 of episode 33 on the “Love at First Science'' Podcast where Dr. Ben Rein speaks into science behind Psychedelics, including the current research on its mechanisms in the body and how it affects behavior. Do you want to learn more about empathy and the effect of psychedelics? Dr. Ben Rein is a researcher in the field of neuroscience and besides that he is also a creator of educational science videos on tiktok and Instagram. He shares how he wants to make science more accessible through his videos and  how to make reading scientific papers easier. On the podcast he talks about the connection between neuroscience and practicing yoga. He presents his concept of “a little bit more”, which is ultimately the secret to keeping your brain young forever. In addition, he explains how aging affects the brain and how healthy and powerful social interactions are to keep a healthy brain. We also venture into the therapeutic value of psychedelics,  the research behind them and what parts of the brain are affected by these controversial drugs. We also touch on the power of sleep, autism, and social media.  --------------------------------------------------------------------------------   Learn More About Dr. Ben Rein: Ben Rein, Ph.D. is a postdoctoral researcher at Stanford University. In his current research, Ben is investigating the neural basis of empathy, and how empathic behaviors can be enhanced. He received his PhD in neuroscience from SUNY Buffalo, earning the Dean's Award for Outstanding Dissertation Research. Ben's thesis focused on autism spectrum disorder and identified key systems in the brain that regulate social behaviors. Outside of the lab, Ben creates educational science videos for an audience of more than 900,000 followers on TikTok, Instagram and BiliBili. In his videos, he summarizes recent research papers, teaches fundamental neuroscience principles, and debunks "viral" videos containing scientific misinformation. Ben's science communication has been recognized with awards from Stanford University, the American Association for the Advancement of Science (AAAS), and the Mind Science Foundation.  --------------------------------------------------------------------------------   Check out & learn more with Dr. Ben Rein: Dr. Ben Rein's Website ⁠Dr. Ben Rein's Youtube ⁠Dr. Ben Rein's Instagram --------------------------------------------------------------------------------  My Socials:   ⁠⁠⁠⁠⁠⁠⁠⁠⁠Celest's Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠Celest's Website ⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠Too Flexible To Feel Good Book

Bill and Darrell discuss why taurine is in so many energy drinks and supplements. Darrell even added it to his suppliments. They have the West Tampa Tobacco Black cigar and drink the Sensei Japanese whiskey. Amino acid in energy drinks makes mice live longer and healthier | Science | AAAS

Guests: Julie Barkmeier-Kraemer, PhD, CCC-SLP, Julie Feuerstein, PhD, CCC-SLP, Shirley Huang, PhD, CCC-SLP, Jennifer Tucker PhD, PT, DPT, PCS - In this episode, Michelle is delighted to be joined by an all-star lineup of colleagues to share how the ASHFoundation is leading the way in expediting research to practice. Dr. Julie Barkmeir-Kraemer, who currently serves as an ASHFoundation Board Member, is also a professor in the Dept of Otolaryngology–Head and Neck Surgery, Director of the Voice, Airway, Swallowing Translational (VAST) Research Lab, Clinic Director of the Voice Disorders Center, and Adjunct Faculty to the Dept of CSD at the University of Utah. They are joined by three recipients of the ASHFoundation's scholarships, including Julie Feuerstein, Ph.D., CCC-SLP, who is an Assistant Professor School of Communication Sciences and Disorders at the University of Central Florida and runs the Early Communication and Play (ECAP) lab there; Shirley Huang, Ph.D., CCC-SLP, who is currently a health and science policy fellow with the Society for Research in Child Development (SRCD)/American Association for the Advancement of Science (AAAS) at the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development; and Jennifer Tucker Ph.D., PT, DPT, PCS is a Clinical Associate Professor in the Program of Physical Therapy at the University of Central Florida, where she serves as the Director of UCF Go Baby Go lab. By the end of this hour, their combined goal is for colleagues to understand the ASHFoundation's mission, identify different research fields that have grown because of their recipient's funding, and find ways to volunteer.

Today on the show, we meet a prosthetic designer and a neuroscientist fascinated with understanding how the brain and body might adapt to something we haven't had before — a third thumb. Dani Clode and Tamar Makin spoke to Short Wave in Washington D.C., at the 2023 annual meeting for the American Association for the Advancement of Science (AAAS).

Today on the show, next-generation energy innovators Bill David and Serena Cussen challenged us to think about the future of clean energy storage. They spoke to Emily Kwong at the 2023 annual meeting for the American Association for the Advancement of Science (AAAS) in Washington D.C.

A couple weeks ago I had a wonderful conversation with my good friend Harriet Mela, the independent researcher from Austria who has helped push the boundaries of soil science and plant physiological understanding. We focused last time on how plants handle water stress, specifically drought and the management practices that can either help or inhibit their natural adaptation to this stress. Harriet also made it clear that she had a lot more to say on this topic and behind the scenes we talked about how to frame another discussion. In that time I shared a link to research done by Dr James White demonstrating how plants can absorb nitrogen from the atmosphere via enzymes in the stomata of their leaves. Turns out that Harriet is of course in close correspondence with James and she suggested that we invite him to our next session to explore the newest discoveries and experiments that they're both conducting. How could I say no to that! So a quick intro to Dr James White to get us oriented. James is Professor of Plant Biology at Rutgers University in New Jersey where he and students conduct research on ecology of microbes that inhabit plants known as endophytes. James White is the author of more than 270 articles and book chapters, and author and editor of seven books on the biology of plant microbes. He is also an elected fellow of the American Association for the Advancement of Science (AAAS), and Associate Editor for journals Symbiosis, Fungal Ecology, MycoScience, Biology and Scientific Reports, and also serves as Chief Editor for the Plant-Microbe Interactions Section of the MDPI journal Microorganisms and has presented extensively at international industry and academic conferences focused on regenerative agriculture, plant biostimulants and crop microbiomes. So as you can imagine, between James and Harriet, we get into some epic material.  Though this session takes us in many directions, a couple of which I probably can't even pronounce correctly, the overarching theme that we explore is the workings of plants and their symbiotic relationships with other organisms that helps them to adapt and overcome stress in their environments. We start by looking at this topic from the perspective of drought tolerance to wrap up the previous conversation, and then we expand from there. We even get into genetic adaptation, the problems with industrially produced seeds, and by the end uncover a key piece of the puzzle that could help you cut the time it takes to transition to regenerative management of your farm into a fraction. Join the discord discussion channel to answer the weekly questions and learn new skills with the whole community Links: https://www.jefflowenfels.com/books-by-jeff-lownfels/ https://kindharvest.ag/courses/ra-cc-carbon-course/

This episode features John Besley, Ph.D., a professor at Michigan State University, who is focused on understanding how scientists communicate complex science to the public. Professor Besley's research includes surveys of thousands of American Association for the Advancement of Science (AAAS) members, where he examines their goals for communication and the tactics they use to achieve them. Professor Besley emphasizes that scientists need to identify their audience-specific behavioral goals and build strategies to achieve them. He also reminds scientists to communicate in a way that makes them perceived as smart, caring, and high in integrity rather than giving into the temptation of flaming people on social media. Professor Besley highlights the importance of scientists communicating their work to have a real-world impact. Surveys show that scientists want to increase literacy, correct misinformation, and encourage people to take actions like wearing masks, planting pollinators, and buying electric vehicles. However, it's important to communicate in a targeted and specific way to address people's perceptions of social norms, risks and benefits, and self-efficacy. Professor Besley advises anticipating obstacles and addressing them proactively in the message. Our discussion also touches on how to approach emotionally charged issues by focusing on evaluative beliefs rather than discrete emotions. Scientists should strive to ensure that decision-making processes are transparent, inclusive, and enable everyone to have a voice. We discuss the importance of understanding the process behind scientific research and communication to combat rejectionism and misinformation, highlighting the need to address specific integrity issues, such as motive and competence, to build trust with audiences. We also delve into the different types of behaviors, such as non-behavioral trust, that are crucial to consider when communicating science. Resources mentioned in the article Strategic Science Communication by John C. Besley, Ph.D.    

The fatty acids in walnuts have long been known to have heart health benefits such as lowering cholesterol and blood pressure. However, a new study shows the heart health benefits may be due to a particular gut bacteria produced when walnuts are consumed. Listen in this week as Dee discusses the details of the study and what it means for the future of heart health.References:American Association for the Advancement of Science (AAAS). (2023, March 25). The heart benefits of walnuts likely come from the gut. EurekAlert!. https://www.eurekalert.org/news-releases/983066Lamontagne, N. D. (2023, March 25). The heart benefits of walnuts likely come from the gut. American Society for Biochemistry and Molecular Biology. https://www.asbmb.org/asbmb-today/science/032523/heart-benefits-walnuts-gut

Rice is arguably the world's most important staple crop. About half of the global population depends on it for sustenance. But, like other staples such as wheat and corn, rice is cultivated annually. That means replanting the fields year after year, at huge cost to both the farmers and the land. For years, scientists have been tinkering with rice strains to create a perennial variety – one that would regrow after harvest without the need to be resewn. Today, Scientist in Residence Regina G. Barber takes a look at one promising perennial rice effort. It's one of a series of interviews we conducted live at the 2023 Annual Meeting of the American Association for the Advancement of Science (AAAS). Curious about extra thumbs, battery breakthroughs and sustainability in space? Check your feed for more live Short Wave episodes from the AAAS Sci-Mic stage in coming weeks! Curious about other scientific innovations? As always, you can reach the show by emailing shortwave@npr.org.

In this episode, we unpack: is ChatGPT Ethical? In what ways?    We interview Dr. Emily M. Bender and Dr. Casey Fiesler about the limitations of ChatGPT – we cover ethical considerations, bias and discrimination, and the importance of algorithmic literacy in the face of chatbots.   Emily M. Bender is a Professor of Linguistics and an Adjunct Professor in the School of Computer Science and the Information School at the University of Washington, where she has been on the faculty since 2003. Her research interests include multilingual grammar engineering, computational semantics, and the societal impacts of language technology. Emily was also recently nominated as a Fellow of the American Association for the Advancement of Science (AAAS).     Casey Fiesler is an associate professor in Information Science at University of Colorado Boulder. She researches and teaches in the areas of technology ethics, internet law and policy, and online communities. Also a public scholar, she is a frequent commentator and speaker on topics of technology ethics and policy, and her research has been covered everywhere from The New York Times to Teen Vogue.   Full show notes for this episode can be found at Radicalai.org.

Oscar seemed like an ordinary kitten when he was adopted by Steere House Nursing and Rehabilitation center in Providence, RI. But the staff and residents at Steere House quickly suspected Oscar had a unique ability. He seemed to be able to predict when someone was going to die. Heads up, this episode is more speculative than usual. And it includes a lot of talk of death. Keep that in mind while listening. Episode Source Material - OscarA Day in the Life of Oscar the CatMaking Rounds with Oscar: The Extraordinary Gift of an Ordinary Cat - Kindle edition by Dosa, David. Politics & Social Sciences Kindle eBooks @ Amazon.com.Classic cases revisited: Oscar the cat and predicting death - PMCMeet Oscar, the Cat that Predicts Death and Provides ComfortThis Cat Sensed Death. What if Computers Could, Too? - The New York TimesCan animals predict death? | HowStuffWorksOscar (therapy cat) - WikipediaCat's 'Sixth Sense': Predicting Death?General on CatsA Brief History of House CatsCats Domesticated Themselves, Ancient DNA ShowsThe Taming of the Cat - PMCStress, security, and scent: The influence of chemical signals on the social lives of domestic cats and implications for applied settings - ScienceDirectDogs Vs. Cats: A Comparison of the 5 Senses – MIDORICIDEDeath and Diseases, further infoWhat to expect when someone is in the last few days of life | Hospice UK.Core body temperatures during final stages of life—an evaluation of data from in-hospital decedents | SpringerLinkHeart attack - Symptoms and causes - Mayo ClinicIdentifying human diamine sensors for death related putrescine and cadaverine molecules | PLOS Computational BiologyProgrammed cell death and apoptosis in aging and life span regulationPredicting DeathDevelopment of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer's diseasePredicting Death: An Empirical Evaluation of Predictive Tools for Mortality | Medical Journals and Publishing | JAMA Internal MedicineStudies on ScentsScents and Senescence: "Old Person Smell" Is Real, but Not Necessarily Offensive - Scientific AmericanThe Scent of Disease: Human Body Odor Contains an Early Chemosensory Cue of SicknessSick People Smell Bad: Why Dogs Sniff Dogs, Humans Sniff Humans, and Dogs Sometimes Sniff Humans - Scientific American Blog NetworkSweat smells like ammonia: Causes and treatmentDisease and odor: An intriguing relationshipThe electronic nose technology in clinical diagnosis: A systematic review12 Diseases Doctors Can Actually Detect Through SmellBio-Detection DogsDiagnostic Accuracy of Canine Scent Detection in Early- and Late-Stage Lung and Breast CancersDogs can discriminate between human baseline and psychological stress condition odours | PLOS ONE  How Do Dogs Sniff Out Diseases? | Discover MagazineThe science of sniffs: disease smelling dogs :: Understanding Animal ResearchTherapy Animals / Our Relationship with AnimalsThe difference between dead and away: An exploratory study of behavior change during companion animal euthanasia - ScienceDirectAnimal-assisted therapy in adults: A systematic review - ScienceDirectAn Evaluation of the benefits that animal-assisted therapy provide to the terminally iII and their familiesAnimal-Assisted Intervention for Autism Spectrum Disorder: A Systematic Literature Review | SpringerLinkMeasuring the Effects of an Animal-Assisted Intervention for Pediatric Oncology Patients and Their ParentsPet Ownership and Cardiovascular Risk | CirculationOther Animal AbilitiesToads able to detect earthquake days beforehand, says study | Animal behaviour | The GuardianSharks use Earth's magnetic field to navigate the seas | Science | AAAS. Fire-chasing beetles sense infrared radiation from fires hundreds of kilometres away. 

James Mitchell Tour is a chemist and nanotechnologist and is the T.T. and W.F. Chao Professor of Chemistry, Comp. Sci., Materials Science & NanoEngineering, at Rice University in Houston, Texas. He conducts research at the Smalley-Curl Institute & NanoCarbon Center. Tour has about 650 research publications and over 200 patents, and is one of the most cited scientists in the world. He was inducted into the National Academy of Inventors in 2015. Tour was named among “The 50 Most Influential Scientists in the World Today” by TheBestSchools.org in 2014; was elected Fellow of the American Association for the Advancement of Science (AAAS), 2009. Tour was ranked one of the Top 10 chemists in the world over the past decade, by a 2009 Thomson Reuters survey. He won the Feynman Prize in Experimental Nanotechnology in 2008, the NASA Space Act Award in 2008 for his development of carbon nanotube reinforced elastomers. www.jmtour.com www.drjamestour.com www.youtube.com/drjamestour twitter.com/drjamestour Dr. Tour's Lecture on the "False Science" Behind Origin of Life Research: https://youtu.be/v36_v4hsB-Y His Graphene Company: www.universalmatter.com Connect with me:

Todays guest is Ben Rein, PhD. Ben is a postdoctoral scholar at Stanford University, and a science communicator on social media. In his current research, Ben is exploring the neural basis of empathy and mechanisms by which empathic behaviors can be enhanced. In 2021, he received his PhD in neuroscience from SUNY Buffalo, earning the Dean's Award for Outstanding Dissertation Research. Ben's PhD thesis research focused on autism spectrum disorder and identified key systems in the brain that regulate social behavior. Ben also creates educational science videos for an audience of more than 850,000 followers on social media. In his videos, he summarizes recent research papers, teaches fundamental science principles, and debunks "viral" videos containing scientific misinformation. Ben has been recognized for his science communication with awards from Stanford University, the American Association for the Advancement of Science (AAAS) and the Mind Science Foundation.   Today Ben reveals 3 things that can make or break your BRAIN HEALTH and we also chat about the importance of sleep, how to know if you are sleep deprived and what you can do to improve your sleep. We also get into the neuroscience of empathy and social interaction, the ins and outs of burnout and so much more! Thanks to this episode's sponsor:   Ned/Mello Magnesium: www.helloned.com/doug Use Promo code "Doug" at checkout to receive 15% off your order    ***DISCLAIMER: Ned also offers other products such as their full spectrum CBD. Please be sure to do your due diligence and make sure that consumption of any products Ned offers are safe for you or the individual consuming it and that it won't conflict with any extenuating circumstances that you or the person consuming it may have for work, school, probation, athletic commissions, etc.   What to Listen For:   0:00 Intro 1:40 These 3 things will make or break your brain health  6:03 The dangers of sleep deprivation & signs that you are sleep deprived 10:49 How to improve the quality of your sleep 14:05 Burnout explained (impact on brain, signs of burnout/how to fix it)  19:60 The neurobiology of social interactions 22:23 How to improve your social skills 24:56 The neuroscience of empathy  30:24 Train your brain to better cope with stress 33:51 Can we change our genes? 40:19 How does sugar impact our brains? 44:52 Detecting signs of depression before it becomes problematic   Episode resources:   Connect with Ben:   Website TikTok Instagram Follow me on Social Media: LinkedIn Instagram Twitter

Dr. John Krystal — All Things Ketamine, The Most Comprehensive Podcast Episode Ever | Brought to you by Athletic Greens all-in-one nutritional supplement, Helix Sleep premium mattresses, and Allform premium, modular furniture. Dr. John Krystal is the Robert L. McNeil, Jr., Professor of Translational Research; Professor of Psychiatry, Neuroscience, and Psychology; Chair of the Department of Psychiatry at Yale University; and Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital.Dr. Krystal is a leading expert in the areas of alcoholism, post-traumatic stress disorder, schizophrenia, and depression. His work links psychopharmacology, neuroimaging, molecular genetics, and computational neuroscience to study the neurobiology and treatment of these disorders. He is best known for leading the discovery of the rapid antidepressant effects of ketamine in depressed patients.He directs/co-directs the Yale Center for Clinical Investigation (CTSA), NIAAA Center for the Translational Neuroscience of Alcoholism, and Clinical Neuroscience Division of the National Center for PTSD (VA).Dr. Krystal is a member of the U.S. National Academy of Medicine; co-director of the Neuroscience Forum of the U.S. National Academies of Sciences, Engineering, and Medicine; Fellow of the American Association for the Advancement of Science (AAAS); and editor of Biological Psychiatry, one of the most selective and highly cited journals in the field of psychiatric neuroscience.He is the co-founder and Chief Scientific Advisor of Freedom Biosciences, a clinical-stage biotechnology platform developing next-generation ketamine and psychedelic therapeutics that recently emerged from stealth in August 2022.ONE VERY IMPORTANT DISCLAIMER: I'm not a doctor, nor do I play one on the Internet. None of the content in this podcast constitutes medical advice or should be construed as a recommendation to use ketamine or psychedelics. There are psychological, physical, and sometimes legal risks with such usage. Please consult your doctor before considering anything we discuss in this episode.Please enjoy!*This episode is brought to you by Helix Sleep! Helix was selected as the #1 overall mattress of 2020 by GQ magazine, Wired, Apartment Therapy, and many others. With Helix, there's a specific mattress to meet each and every body's unique comfort needs. Just take their quiz—only two minutes to complete—that matches your body type and sleep preferences to the perfect mattress for you. They have a 10-year warranty, and you get to try it out for a hundred nights, risk-free. They'll even pick it up from you if you don't love it. And now, Helix is offering up to 200 dollars off all mattress orders plus two free pillows at HelixSleep.com/Tim.*This episode is also brought to you by Athletic Greens. I get asked all the time, “If you could use only one supplement, what would it be?” My answer is usually AG1 by Athletic Greens, my all-in-one nutritional insurance. I recommended it in The 4-Hour Body in 2010 and did not get paid to do so. I do my best with nutrient-dense meals, of course, but AG further covers my bases with vitamins, minerals, and whole-food-sourced micronutrients that support gut health and the immune system. Right now, Athletic Greens is offering you their Vitamin D Liquid Formula free with your first subscription purchase—a vital nutrient for a strong immune system and strong bones. Visit AthleticGreens.com/Tim to claim this special offer today and receive the free Vitamin D Liquid Formula (and five free travel packs) with your first subscription purchase! That's up to a one-year supply of Vitamin D as added value when you try their delicious and comprehensive all-in-one daily greens product.*This episode is also brought to you by Allform! If you've been listening to the podcast for a while, you've probably heard me talk about Helix Sleep mattresses, which I've been using since 2017. They also launched a company called Allform that makes premium, customizable sofas and chairs shipped right to your door—at a fraction of the cost of traditional stores. You can pick your fabric (and they're all spill, stain, and scratch resistant), the sofa color, the color of the legs, and the sofa size and shape to make sure it's perfect for you and your home.Allform arrives in just 3–7 days, and you can assemble it yourself in a few minutes—no tools needed. To find your perfect sofa and receive 20% off all orders, check out Allform.com/Tim.*For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsorsSign up for Tim's email newsletter (5-Bullet Friday) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Discover Tim's books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissYouTube: youtube.com/timferrissFacebook: facebook.com/timferriss LinkedIn: linkedin.com/in/timferrissPast guests on The Tim Ferriss Show include Jerry Seinfeld, Hugh Jackman, Dr. Jane Goodall, LeBron James, Kevin Hart, Doris Kearns Goodwin, Jamie Foxx, Matthew McConaughey, Esther Perel, Elizabeth Gilbert, Terry Crews, Sia, Yuval Noah Harari, Malcolm Gladwell, Madeleine Albright, Cheryl Strayed, Jim Collins, Mary Karr, Maria Popova, Sam Harris, Michael Phelps, Bob Iger, Edward Norton, Arnold Schwarzenegger, Neil Strauss, Ken Burns, Maria Sharapova, Marc Andreessen, Neil Gaiman, Neil de Grasse Tyson, Jocko Willink, Daniel Ek, Kelly Slater, Dr. Peter Attia, Seth Godin, Howard Marks, Dr. Brené Brown, Eric Schmidt, Michael Lewis, Joe Gebbia, Michael Pollan, Dr. Jordan Peterson, Vince Vaughn, Brian Koppelman, Ramit Sethi, Dax Shepard, Tony Robbins, Jim Dethmer, Dan Harris, Ray Dalio, Naval Ravikant, Vitalik Buterin, Elizabeth Lesser, Amanda Palmer, Katie Haun, Sir Richard Branson, Chuck Palahniuk, Arianna Huffington, Reid Hoffman, Bill Burr, Whitney Cummings, Rick Rubin, Dr. Vivek Murthy, Darren Aronofsky, Margaret Atwood, Mark Zuckerberg, Peter Thiel, Dr. Gabor Maté, Anne Lamott, Sarah Silverman, Dr. Andrew Huberman, and many more.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.